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 Histone proteins are proteins found in eukaryotic cells that associate with DNA to form 
the most basic structural unit of chromatin, called nucleosomes. The post-translational 
modifications of histones regulate developmental competence in bovine oocytes and early 
embryos.  The difference in developmental competence between in vitro matured oocytes and 
in vivo matured oocytes was used to investigate the accumulation of transcripts for histone 
methyltransferases (HMTs) during oocyte maturation.  Methyltransferases ASH1L, EHMT2, 
SUV39H1 and KDM6B were selected as genes of interest. Transvaginal ultrasound-guided 
aspiration (TUGA) was used to collect immature and in vivo matured bovine cumulus-oocyte 
complexes (COCs). Immature COCs collected via TUGA were randomly assigned to either the 
immature or the in vitro mature treatments. Transcriptome analysis was performed in COCs, 
oocytes, and cumulus cells. Results showed no differences in transcriptome levels between 
immature and in vivo treatments, suggesting that there are no major accumulations of 
transcripts for HMTs during the antral phase of oocyte maturation in vivo. Higher accumulations 
of transcripts for the EHMT2 and ASH1L genes were found in the in vitro maturation Treatment 
for COCs and oocytes (p = 0.005 and p = 0.001, respectively). Immunocytochemistry was used 
to investigate the consequences of this increase in transcripts accumulation for HMTs during in 
vitro maturation of oocytes. Methylation levels of lysine 9 in histone 3 measured in both oocytes 
at the metaphase II stage and early embryos showed that the increase in the accumulation of 
transcripts coding for HMTs during in vitro maturation correlates with a decrease in the level of 
methylation of lysine 9 in histone 3 in oocytes at the metaphase II stage, as well as a decrease 
in the levels of methylation of lysine 9 in histone 3 in the blastomeres of early cleaving embryos. 
The decrease in the levels of tri-methylation of lysine 9 in histone 3 potentially affect the 
capacity of the oocyte and early embryo to silence gene and stabilize heterochromatic regions 





 Epigenetic reprograming studies the molecular modifications of DNA, DNA associated 
proteins and chromatin associated with changes in gene expression. These modifications 
contain inheritable information that does not depend upon the sequences of bases in the DNA 
molecule, and are usually referred as the epigenetic status of a cell. Genome-wide modifications 
of the epigenetic status of the cell (epigenetic reprograming) occur twice naturally during early 
embryo development: soon after fertilization and during gametogenesis. After fertilization, the 
paternal and maternal genomes must undergo dramatic changes in their nuclear morphology 
and chromatin structure to achieve a configuration that allows the gene expression pattern 
required to progress further in development. 
 The epigenetic status of a cell can be modified by the methylation of cytosine bases in 
the DNA, the post-translational modification of histone proteins, the positioning of the 
nucleosomes, and topological changes in the chromosomes. The modification of histones is one 
of the most versatile mechanisms involved in epigenetic reprograming because they can be 
used as markers for proteins that modify chromatin structure. As a general rule, enzymes that 
covalently modify histones target specific amino acids and a different enzyme is responsible for 
removing the epigenetic mark. 
 Histones can be methylated on either lysine or arginine residues. The numerous lysine 
and arginine residues on the histone tail, the multiple levels of methylation that each residue can 
take, and the possible combination of multiple methylation sites, on top of the possibility of 
methylation marks interacting with other types of epigenetic marks, makes histone methylation a 
complex, flexible, and effective regulatory mechanism (Shi and Whetstine, 2007).   
  EHMT2 (Euchromatic histone-lysine N-methyltransferase) and SUV39H1 (Homolog 1 of 
the position-effect variegation 3-9) are both histone methyltransferases that catalyze the mono-, 
di-, and tri-methylation of lysine 9 in histone 3 (Tachibana et al., 2002; Park et al., 2014). The 
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difference in their activity is based on the tendency of EHMT2 to associate with silent genes in 
euchromatic regions whereas SUV39H1 is a signal for pericentric heterochromatin and for the 
establishment of transcriptional repression.  
 ASH1L (Absent, Small or Homeotic disk 1) is a histone methyltransferase involved in 
epigenetic reprograming due to its capacity to catalyze the methylation of histone 3 at lysine 4. 
This epigenetic mark is important during early embryo development because it has been 
associated with regions of active gene transcription and very stable chromatin structure 
(Gregory et al., 2007; Gao et al., 2010). KDM6B is a demethylase enzyme, having an 
antagonistic roll to the histone methyltransferases described earlier. KDM6B has the capacity to 
remove repressive marks, prevent the activity of heterochromatic proteins, and enhance gene 
expression (Agger et al., 2007).  
 ASH1L, EHMT2, SUV39H1, and KDM6B work together with other epigenetic markers to 
modify the epigenetic landscape of the DNA in the paternal and maternal gametes in order to 
create an all-new epigenetic landscape for the embryo that supports both the maternal-zygote 
transition of gene regulation and the developmental potential of the early embryo. 
The present document describes a series of three experiments that use the well-
established difference in developmental potential between in vitro matured oocytes and in vivo 
matured oocytes to study the accumulation of transcripts coding for ASH1L, EHMT2, SUV39H1, 
and KDM6B methyltransferase enzymes in cumulus-oocyte complexes, cumulus cells, and 
oocytes. A fourth experiment investigates the consequences of irregular accumulation of 
transcripts coding for histone methyltransferases by evaluating the levels of tri-methylation of 
lysine 9 in histone 3 when comparing in vitro versus in vivo matured oocytes. One further step is 
taken in the fifth experiment by comparing the epigenetic landscape of in vitro fertilized embryos 






In 1962 Sir John B. Gurdon replaced the immature nucleus in the egg of a frog with the 
mature nucleus of a differentiated frog’s intestinal cell. The modified egg successfully developed 
into a tadpole (Gurdon, 1962). With this experiment, Gurdon demonstrated that the regulatory 
mechanisms that determine the subset of genes to be expressed by a given cell can be 
modified. Epigenetic reprograming studies the molecular modifications of DNA, DNA associated 
proteins, and chromatin associated with changes in gene expression. These modifications 
contain inheritable information that does not depend upon the sequences of bases in the DNA 
molecule and are usually referred to as the epigenetic status of a cell. 
Genome-wide modifications of the epigenetic status of the cell (epigenetic reprograming) 
occur naturally twice during early embryo development: during gametogenesis and soon after 
fertilization.  Experimentally, epigenetic reprograming can be induced by fusing somatic cells 
with embryonic stem cells, by cloning via nuclear transfer, and by induction of pluripotency with 
core transcription factor procedures. Also, changes in gene expression patterns similar to those 
described during epigenetic reprograming have been described in some pathological conditions 
(Koike et al., 2014; Zhang et al., 2014).  
During gametogenesis primordial germ cells must change their somatic bi-parental 
epigenetic marks and acquire the adequate epigenetic marks for gametes of the gender of the 
embryo. After fertilization, the paternal and maternal genomes must undergo dramatic changes 
in their nuclear morphology and chromatin structure in order to achieve a configuration that 
allows the gene expression pattern required to progress further in development.  
However, transcription from gametic genomes is tightly regulated for reasons associated 
with avoidance of activation of selfish DNA elements, reprograming of the genome, and dense 
packaging in the male pronuclei (Blaxter, 2014). Therefore, the maternal gamete must provide 
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either the proteins or the transcripts and the translational machinery responsible for controlling 
the developmental progress of the early embryo.  
The epigenetic status of a cell can be modified by the methylation of cytosine bases in 
the DNA, the post-translational modification of histone proteins, the positioning of the 
nucleosomes, and topological changes in the chromosomes. The modification of histones is one 
of the most versatile mechanisms involved in epigenetic reprograming. Histones are proteins 
that associate with DNA in the chromosomes of eukaryotic cells. Their structural function is to 
organize the DNA in the form of nucleosomes, which are further arranged into higher-order 
chromatin structures. By controlling chromatin structure, histone proteins regulate the 
accessibility of proteins to DNA, especially transcription factors and RNA polymerase, therefore 
modifying gene expression. 
Consequent with their dual function, histone proteins have two regions: the core and the 
N-terminal tails. The core is characterized by a close attachment of the protein to the DNA lead 
by hydrogen bonds, hydrophobic interactions, and salt linkages. The N-terminal tails are 
exposed on the outside of the nucleosome and are considered the regulatory regions because 
they interact with other elements to control chromatin structure and function.  
The post-translational modifications of histones (via covalent modifications of the histone 
N-terminal tails) serve as markers that recruit specific protein complexes. These markers allow 
or deny access to the DNA by other protein complexes, thereby regulating biological functions. 
The amino acid side chains of the histone tails are subject to covalent modifications including 
acetylation, phosphorylation, ubiquitination, and methylation. These modifications regulate 
diverse chromatin functions such as gene expression, DNA replication, and chromosome 
segregation (Zhang and Reinberg, 2001). 
The post-translational modification of histone proteins is one of the mechanisms that 
modifies the epigenetic status of a cell.  Other mechanisms include the methylation of cytosine 
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bases in DNA, the repositioning of nucleosomes, topological changes in chromosomes, and the 
relative positioning of genes within the nucleus.  
Proteins that carry out epigenetic modifications do not act alone, but interact with one 
another, often by forming large protein complexes. These protein complexes regulate high-order 
chromatin structure and the accessibility to chromatin of proteins that regulate transcription (Li, 
2002). The modification of the epigenetic status of a cell at any given time can be started by 
single residue modifications in the histone tail, or by a combination of modifications in the same 
histone or even in different histone proteins within the same nucleosome. The function of a 
given histone modification is given by the type of regulatory protein it recruits (Bannister and 
Kouzarides, 2005).  
The covalent addition of marks in histone tails is a dynamic process, with marks being 
added and removed at different rates depending on their chromosomal location, status of the 
cell in the cell cycle, and environmental conditions and stimulus. This implies that all post-
translational modifications of histones must be reversible, an idea that was very controversial 
only ten years ago. Nowadays, a large number (but not all) of the enzymes responsible for 
these modifications have been identified and characterized (Beisel et al., 2002; Andreu-Vieyra 
et al., 2010). As a general rule, enzymes that covalently modify histones target specific amino 
acids and a different enzyme is responsible for removing the epigenetic mark.  
2.1 Histone Methylation 
Histones can be methylated on either lysine or arginine residues. The numerous lysine 
and arginine residues on the histone tail, the multiple levels of methylation that each residue can 
acquire, and the possible combination of multiple methylation sites on top of the possibility of 
methylation marks interacting with other types of epigenetic marks makes histone methylation a 
complex, flexible, and effective regulatory mechanism (Shi and Whetstine, 2007).  
Methylation of histone proteins induces changes in chromatin structure, but the relatively 
small size of methyl groups and the fact that their addition to lysine and arginine residues does 
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not neutralize their charges makes it unlikely that methylation alone changes chromatin 
structure enough to induce changes in gene expression (Bannister and Kouzarides, 2005). It is 
more likely that the modification of histone tails creates binding sites for regulatory proteins with 
specific binding domains.  
The mechanisms by which histone methyltransferases recognize the specific sections of 
chromatin to be methylated is not clearly understood. It has been postulated that 
methyltransferases can be recruited by DNA binding factors or by the transcriptional machinery. 
They may also be recruited by proteins capable of recognizing methylation and other epigenetic 
marks on histone residues. These proteins reside within complexes that are associated with 
enzymatic activities operating on the chromatin template (Ruthenburg et al., 2007). There is 
also some evidence that non-coding RNAs transcribed from specific regions within target genes 
have the ability to recruit histone methyltransferases and DNA methyltransferases to the tails of 
histone 3 proteins associated with the target gene (Sanchez-Elsner et al., 2006). This 
mechanism, however, was described in the Drosophila and it is not yet known if it occurs in 
mammalian cells. The authors propose, though, that these types of epigenetic mechanisms are 
generally well preserved throughout evolution.  
There are three main groups of proteins that regulate histone methylation as an 
epigenetic mark. The trithorax group is the main family of proteins responsible for maintaining 
chromatin in a permissive state via histone methylation, and the Polycomb group mediates the 
addition of methyl residues that propend for repressive configurations of chromatin (Gao et al., 
2010). The third group, the Jumonji C domain containing family, is mainly responsible for 
removing the methylation marks. 
Methylation of histone tails was previously considered an irreversible modification. It was 
not until 2005 that members of the Jumonji C domain containing proteins started to be identified 
by their histone demethylase activity (Trewick et al., 2005).  Since then, the JmjC domain has 
been identified in more than one hundred proteins, in organisms from bacteria to eukaryotes. 
7 
 
The large number of enzymes with potential to demethylate histone proteins, the multiple 
residues in the histone tails susceptible of methylation, and the possible interactions between 
multiple modifications suggest that demethylases represent an important mechanism to 
dynamically regulate histone methylation as an epigenetic mark (Shi and Whetstine, 2007).  
There seems to be differences in the regulatory mechanisms of histone methylation 
between gametes and somatic cells in mice. In the oocyte, methylation of specific histone 
residues are enzyme-specific, and transgenic mice carrying double mutations of specific histone 
methyltransferase genes fail to fertilize and/or develop; whereas, genetically modified cumulus 
cells with double mutations of single histone methyltransferase genes show an increase in the 
levels of transcripts of similar enzymes with a compensatory increase of the epigenetic 
modification (Andreu-Vieyra et al., 2010). 
2.1.1. Methylation of Lysine Residues 
Histone 3 can be methylated at lysine residues 4, 9, 27, 36, and 79; histone 4 can be 
methylated at lysine 20 (H3K4, H3K9, H3K27, H3K36, H3K79, H4K20, respectively). Lysine 
residues can be mono-, di- or tri-methylated (Gregory et al., 2007). Both the site and the extent 
of lysine methylation affect the interaction between chromatin and effector proteins.  
Since the outcome of any epigenetic mark depends on the location of the modification, 
the combination of one or more modifications, and the enzyme involved in the particular 
modification, the biological outcomes of methylation of lysine residues in histone proteins are 
associated with multiple and diverse cell processes (Nishioka et al., 2002). Lysine methylation is 
involved in the progression of the cell cycle, DNA replication and apoptosis. It can be a mark of 
accessible DNA for effector proteins or it can recruit proteins that organize heterochromatin and 
induce gene silencing. When regulation is lost, lysine methylation of histone tails has been 
associated with pathological conditions such as prostate, breast, and hematopoietic cancers, as 
well as neurological disorders (Shi and Whetstine, 2007). Sometimes antagonist marks coincide 
to co-regulate the expression of pluripotency genes.  
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Therefore, the methylation of lysine residues in histone tails can be better understood by 
studying specific lysine residue modifications in combination with the enzyme responsible for 
the modification. 
2.1.1.1. Methylation of Histone 3 at Lysine 4 
Methylation of histone 3 at lysine 4 is an evolutionarily conserved mark associated 
mainly with transcriptionally active chromatin, although transcriptional repression has been 
described in association with H3K4me2/3 in some cases (Shi et al., 2006). The methylation of 
histone 3 at lysine 4 was first described by Honda et al, in 1975. They were characterizing other 
known methylation forms in histone 3 when they discovered what they described as “an 
additional minor site for histone 3 methylation” (Honda et al., 1975b).  At that time, methylation 
of histones was thought to be not only a stable, irreversible modification but also part of a 
temporal sequence of events that begins with histone synthesis and is followed by histone 
acetylation, deacetylation, methylation, and phosphorylation (Honda et al., 1975a). 
High levels of H3K4 tri-methylation are regularly associated with the 5’ region of the 
majority of active genes in vertebrates, with many authors suggesting a strong positive 
correlation between this modification and an increase in transcription rates, active polymerase II 
occupancy, and histone acetylation (Bernstein et al., 2005; Ruthenburg et al., 2007). The di-
methylated stage of H3K4 has been associated with open chromatin frames, but not with 
transcriptional activation, since tri-methylated H4 accumulates around the promoter region of 
transcriptionally active genes but di-methylated H3K4 does not (Bernstein et al., 2002; Santos-
Rosa et al., 2002).  
There are some situations where methylation of H3K4 does not follow the criteria 
described previously. One example is the regions where genes of the Hox family are located. 
Genes of the Hox family show broad patterns of methylation along the whole cluster, instead of 
just around the promoter region, and it has been suggested that this difference in the 
methylation patterns has to do with the role of these genes during early embryo development 
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(Bernstein et al., 2005).  Another exception occurs when H3K4me2/3 is recognized by proteins 
of the histone deacetylase complex, such as ING2. In these cases transcriptional repression 
occurs (Shi et al., 2006). 
The biological effects of methylation of lysine 4 in histone 3 acquire a new order of 
complexity as regulatory mechanisms when methylation of H3K4 interacts with other epigenetic 
marks. For example, the acetylation of histone 3 tails is followed by the methylation of lysine 4 in 
histone 3, resulting in the opening of the chromatin structure (Strahl et al., 1999).  Methylation of 
H3k4 also precludes methylation of H3K9 by SUV39H1, but not by KDM6B (Nishioka et al., 
2002), affecting the formation of heterochromatin but not gene silencing within euchromatic 
regions. Also, H3K4 methylation can have a regulatory effect on chromatin structure and gene 
expression, since it interferes with demethylases such as NuRD binding to chromatin (Nishioka 
et al., 2002).  
The role of methylation of lysine 4 during early development is still a matter of study. In 
humans, there is evidence that the tri-methylation of lysine 4 in histone 3 is a constant 
epigenetic mark throughout development, beginning in oocytes at the germinal vesicle stage, 
going into the metaphase II stage, and in pre-implantation embryos. (Zhang et al., 2012). The 
relative abundance of this specific epigenetic mark, measured using immunocytochemistry, 
showed that there is no significant difference in the levels of tri-methylation of H3K4 between 
oocytes at different stages of maturation. However, there was an increase in the relative 
abundance of H3K4me3 in early embryos compared with oocytes and the levels decreased to 
the lowest values by the occurrence of genomic activation in the embryos. 
 Studies with animal models suggest that tri-methylation of H3K4 is a common mark of 
the oocyte genome in most mammalian species. In mammalian early embryos, the H3K4me3 
mark has two elements of interest. First, H3K4me3 is an asymmetric mark in the parental 
pronuclei, since high levels of H3K4me3/2 have been found in the female pronuclei, but not in 
the male counterpart (Ross et al., 2008).  Secondly, levels of H3K4me3 decreased after 
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fertilization in pig embryos (Gao et al., 2010).  The interpretation of these results remains 
controversial, questioning the role of H3K4 methylation in chromatin remodeling and gene 
expression in the early embryo.  It is not clear whether the decrease in H3K4me3 levels is due 
to active demethylation or if it is the result of dilution caused by the addition of non-methylated 
histones during cell division. 
Thus far, nine enzymes have been identified as being capable of methylating lysine 4 in 
histone 3 in vertebrates. These enzymes include ASH1L, SET7/9, SMYD3, Meisets, and five 
members of the Mixed Lineage Leukemia proteins family (MLL). Out of these nine, ASH1L is the 
only one associated directly with early embryo development (Gregory et al., 2007; Gao et al., 
2010).  
2.1.1.1.1. Absent, Small, or homeotic Disk 1 (ASH1L) 
ASH1L is the common name to refer to the mammalian homologue of the Drosophila 
melanogaster tritorax group protein, called Absent, Small or Homeotic disk 1. It has been also 
called “Absent, Small, or Homeotic like Drosophila”, “Absent, Small, and Homeotic disk protein 1 
homologue”, “Lysine N-methyltransferase 2H”, “KMT2H”, and “Histone Lysine N-
methyltransferase”, among others. Experimentally, ASH1L has shown the capacity to methylate 
histone 3 at lysines 4, 9 and 20 in the Drosophila (Beisel et al., 2002). However, its spatial 
distribution in vertebrates correlates well with H3K4me3, but not as well with heK9 and H3K20 
(Gregory et al., 2007). 
ASH1L is a large, multi-domain protein complex that contains multiple motifs associated 
with chromatin remodeling. The PRE-SET and the SET domain are responsible for the 
methyltransferase activity (Beisel et al., 2002), but it contains at least nine more motifs that can 
potentially interact with chromatin-protein complexes. It has been proposed that ASH1L uses 
these motifs to establish epigenetically active structures during epigenetic activation (Gregory et 
al., 2007). ASH1L actively interacts with Heterochromatin Protein 1 (HP1), Drosophila Polycomb 
(Pc) and the Chromatin Remodeling Complex (CRC) (Beisel et al., 2002). 
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High levels of ASH1L transcripts were found at the 4-cell stage in porcine oocytes. The 
high level of transcripts matched the high levels of tri-methylation of H3K4 reported at the same 
time. These findings suggest that ASH1L plays an important role in stabilizing chromatin 
structure and keeping the open-frame status required for the porcine embryo to progress 
through early development and genomic activation (Gao et al., 2010).  
ASH1L occupies the 5’-transcribed region of active genes and it is not usually 
associated with the transcribed region of inactive genes, unlike MLL1. Therefore, it has been 
postulated that there is a synergic or coupled activity between ASH1L and MLL1 in many 
mammalian genes, implying that different methyltransferase enzymes from the tritorax family 
might work together during activation of transcription (Gregory et al., 2007). 
The close association between a peak in the expression of ASH1L and the activation of 
a cluster of genes of the Hox family in pig embryos has been used to postulate that ASH1L-
mediated H3K4 tri-methylation plays a major role during development in the pre-implantation 
embryo (Gao et al., 2010). These findings contradict the low levels of ASH1L activity described 
by Whitworth in the 4-cell porcine embryo (Whitworth et al., 2005).  
2.1.1.1.2. SET Domain Containing Protein 7 
First described in 2002 (Nishioka et al., 2002), Set 9 is a histone 3 lysine 4 
methyltransferase mainly associated with open chromatin frames and active gene transcription. 
Set 9 methylate activities are determined by a 50kD single polypeptide containing a SET motif 
as a catalytic unit, like most of mammalian histone methyltransferases. However, regardless of 
the evolutionarily highly conserved origins of histone proteins and its modifiers, it lacks the PRE-
SET and POST-SET motifs that other enzymes of this family require for their catalytic activity 
(Nishioka et al., 2002). This is relevant because the PRE-SET and POST-SET domain are 
responsible for recognizing the specific residues where HMT enzymes are to be recruited for 
activity. This requires SET 9 to be directed to the selected nucleosomes by a yet unidentified 
factor that recognizes the right substrates to be modified.  
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SET 9 also seems to facilitate transcription by a slightly different mechanism than most 
HMTs. It does not recruit protein complexes that enhance transcription; SET 9 precludes the 
association of NuRD (a histone 3 deacetylase enzyme associated with gene silencing) and 
SUV39H1 (a H3K9 methyltransferase associated with gene silencing) with the tail of histone 3 
(Nishioka et al., 2002). Moreover, SET 9 precludes the activity of SUV39H1 but has no effect on 
EHMT2. This means that the recognition of residues by these two H3K9 methyltransferases can 
be independently regulated by other modifications within the same tail (Nishioka et al., 2002).  
2.1.1.2. Methylation of Histone 3 at Lysine 9 
Methylation of lysine 9 in histone 3 proteins has been associated with transcriptional 
gene silencing and it is considered the epigenetic mark of constitutively repressed 
heterochromatin. It has been well established that H3K9me3 complements DNA methylation, 
inhibits serine phosphorylation (Chen et al., 1999), and actively participates in the recruitment of 
heterochromatin protein 1 (HP1) during the formation of heterochromatin leading to gene 
silencing. Furthermore, the tri-methylation of lysine 9 at histone 3 has also been recently 
associated with active genes (Gregory et al., 2007).  
  Five histone 3 lysine 9 methyltransferases have been identified so far and they display 
subtle differences in their ability to do so. EHMT1 and EHMT2 mediate di-methylation in 
euchromatic regions, SUV39H1 and SUV39H2 regulate formation of heterochromatin and 
SETDB1 has been associated with the silencing of retrovirus-like elements dispersed in the 
euchromatic regions in mammalian cells (Park et al., 2011).  
Methylation at H3K9 is generally associated with repressive chromatin status; however, 
the degree of methylation modifies the significance of the modification. For example, the tri-
methylated state of lysine 9 in histone 3 is associated with pericentric heterochromatin, whereas 
the mono- and di- methylated status of lysine 9 are more associated with silent domains within 
euchromatic regions (Lehnertz et al., 2003; Peters et al., 2003). However, tri-methylation of 
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H3K9 can also serve as a mark for active gene expression when the tri-methylated histones are 
located within the body of the gene (Shi and Whetstine, 2007). 
The presence of tri-methylated H3K9 has been described in immature ovine oocytes, 
and remains during oocyte growth and maturation. It has been proposed that H3K3me3 works 
synergistically with the progressive methylation of DNA in maturing oocytes to create a 
repressed chromatin status in the fully differentiated oocyte and to underlie the silencing of 
imprinted genes (Russo et al., 2013). This synergic mechanism between histone methylation 
and DNA methylation has been described as fundamental in the establishment and 
maintenance of epigenetic gene silencing regulation of cell determination and function (Vire et 
al., 2006). 
Both the tri-methylated and the di-methylated forms of H3K9 are present in the 
developing mouse oocyte, and the levels of methylation change in similar manners, suggesting 
that both stages are under the same regulatory mechanism (Liu et al., 2004). In mice, the 
methylation status present in H3K9 during oocyte maturation and growth is maintained after 
fertilization, whereas the paternal genome remains under-methylated even though H3K9 HMTs 
transcripts and enzymes are present in the ooplasm after fertilization. Paternal and maternal 
genomes remained asymmetrically methylated until genomic activation, where methylation 
levels increased symmetrically. These findings suggest that H3K9 HMTs are inactive during 
early embryonic stages and that the role of H3K9 methylation is not to regulate heterochromatin 
formation and gene expression in the early embryo, but to mark the maternal genome so it can 
be differentiated from the paternal genome by the cellular machinery (Liu et al., 2004).  
2.1.1.2.1. Euchromatin Histone-Lysine N-Methyltransferase 2 (EHMT2) 
EHMT2 also has been called “Histone3-K9 methyltransferase”, “Lysine N-
Methyltransferase 1C”, “Protein G9a”, “G9a”, “Lysine 9 Specific 3”, “H3-K9-HMTase 3”, “HLA-B-
Associated Transcrip 8”, “Chromosome 6 open reading frame 30”, “GAT8”, and “Ankyrin 
Repeat-Containing Protein”. It regulates mono- and di-methylation of histone 3 at lysine 9 in 
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euchromatic regions and has been associated with inactive chromatin stages and with 
repression of gene expression during embryogenesis (Park et al., 2011). 
There have been two mechanisms proposed for EHMT2: it creates local heterochromatic 
architecture in euchromatic regions by methylating H3K9 that recognize subpopulations of HP1 
proteins, and/or (since it also methylates H3K27 in vitro) histone 3 proteins methylated at both 
lysine residues may recruit chromatin modifying proteins that influence chromatin structure and 
gene expression (Tachibana et al., 2002). 
There is an early embryonic lethality on EHMT2 -/- mice, with the developmental arrest 
occurring from the E9 stage until the E12 stage (the time of neural plate formation, formation of 
amniotic cavities, and the end of gastrulation in mice) characterized by the reorganization of 
tissues, widespread alterations in gene expression profiles, and chromatin reorganization 
(Tachibana et al., 2002). These elements suggest that EHMT2 mediated histone methylation of 
euchromatin is a key component of the mechanisms that regulate early stages of 
embryogenesis. Retardation of embryonic growth was also noticed, which was explained by the 
significant increase of apoptotic cells in EHMT2 -/- embryos.  
EHMT2 deficiency affects genes that are imprinted in the trophoblast which are not 
dependent on DNA methylation for the somatic maintenance of their allelic silencing (Park et al., 
2011). However, there was no significant change in the in vitro developmental potential of 
porcine embryos injected with EHMT1/2 RNAi; changes in the transcript abundance of eIF1A, 
but not OCT4, NANOG, or SOX2 suggest that only a subset of genes that undergo changes in 
transcript abundance are regulated by histone modifying enzymes (Park et al., 2011). 
2.1.1.2.2. Suppressor of variegation3-9 Homolog 1 (SUV39H1) 
Also called “Position-Effect Variegation 3-9 Homolog”, “KMT1A”, “Lysine N-
methyltransferase 1A”, and “H3-K9 HMTase 1”, SUV39H1 has classically being associated with 
inactive chromatin and repression of gene expression because SUV39H1 mediates the 
recruitment of HP1 via tri-methylation of H3K9.  Moreover, it is considered to control the 
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inheritance of repressive chromatin regions since SUV39H1 is the trans-generational signal for 
pericentric heterochromatin formation in mouse early embryos, which plays a crucial role in 
chromosome segregation and establishment of transcriptional repression (Tachibana et al., 
2002).  
Additional roles other than heterochromatin formation have been proposed for H3K9 tri-
methylation by SUV39H1.  It has been implicated in chromatin remodeling during DNA repair 
since modifications in the interaction of SUV39H1 and chromatin have resulted in altered DNA 
repair mechanisms and modification of the lifespan of mice (Liu et al., 2013).  SUV39H1 has 
been recently associated with the mechanisms of chromosome condensation and alignment, 
since mutant forms of the enzyme result in misalignment and failure of chromosome 
segregation during mitosis (Chu et al., 2012; Wang et al., 2013).  Moreover, SUV39H1 has been 
suggested to play a role in the regulation of the cell cycle by facilitating the replication of 
heterochromatin (Chu et al., 2012).  
The cell cycle dependent protein kinase CDK2 has the potential to phosphorylate 
SUV39H1 at serine 391 during G1-S transition in vivo and in vitro (Park et al., 2014). The 
phosphorylated SUV39H1 dissociates from chromatin, allowing histone demethylases such as 
JMJD2A to access to heterochromatic loci. The induced structural modification of 
heterochromatin would facilitate DNA replication and the progression through the cell cycle.  
The tri-methylation of H3K9 by SUV39H1 works synergistically with DNA 
methyltransferases Dnmt3a and Dnmt3b to generate heterochromatic DNA at pericentric 
satellite repeats (Lehnertz et al., 2003). The control of the DNA methylation process at 
centromeric repeats seems to be regulated by a different pathway, since SUV39H1 mutant cells 
were capable of undergoing chromatin condensation at the centromeric repeats. 
Lastly, it has been suggested to have a specific role during early embryo cleavage 
because the injection of RNAi targeting SUV39H1 in porcine embryos affected in vitro 
development. There was a decrease in cell number in embryos injected with the RNAi, but there 
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was no interference with the transcript abundance of NANOG, SOX2, OCT4 or eIF1A. Results 
indicated that this HMT is not involved in the regulation of transcription of these genes, and their 
effect has to be in other epigenetic pathways which also control early embryo development 
(Park et al., 2011).  Also, double mutant SUV39h1/2 -/- mice are not lethal, questioning the 
relevance of the role of this enzyme in mammalian embryonic development (Tachibana et al., 
2002). 
2.1.1.3. Methylation of Histone 3 at Lysine 27 
Methylation of lysine 27 in histone 3 is a repressive modification and it is considered the 
epigenetic mark of facultative heterochromatin. The Polycomb repressive complex 2 is 
responsible for keeping lysine 27 at histone 3 in a tri-methylated or di-methylated state, and  it 
also has the ability to recruit repressive proteins that modify the chromatin structure into a 
repressive state (Gao et al., 2010). UTX and KDM6B are enzyme members of the trithorax 
family responsible for the removal of methyl groups of the tri-methylated and di-methylated state 
of H3K27. This group of enzymes is characterized by the presence the JmjC domain, which is 
the motif with the demethylase activity. KDM6B induces strong demethylation of H3K27 in vivo 
and causes delocalization of Polycomb proteins in vivo (Agger et al., 2007).  Other regulatory 
mechanisms that control or decide the methylation status of H3K27 and its biological activity are 
yet to be discovered.   
Some authors report the levels of relative abundance of tri-methylation of lysine 27 in 
histone 3 to be stable during oocyte maturation and early embryo development in humans, and 
that only embryos around the time of genomic activation show a significant decrease in the 
global methylation pattern of the nuclei (Zhang et al., 2012). Some other authors report a rapid 
decrease in the levels of tri-methylation of H3K27 during embryogenesis and stem cell 
differentiation. The former group suggests that H3K27 is required for stem cell renewal, is 
considered important in maintaining pluripotency, and plays a role in the regulation of the 
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expression of the three key pluripotency genes OCT4, NANOG and SOX2 during early 
differentiation in embryonic stem cells. 
Studies in humans reported that after fertilization only one of the two pronuclei (the one 
closest to the polar bodies) had a positive signal for H3K27me3, whereas both of the polar 
bodies produced a strong H3K27me3 signal. The authors considered the H3K27 tri-methylated 
pronuclei as the maternal one, and the pronuclei without H3K27me3 as the paternal one (Zhang 
et al., 2012). This phenomenon has also been described in bovine embryos (Ross et al., 2008). 
In early porcine embryos, the levels of methylation of H3K27 follow the levels of histone 
methyltransferase transcripts. At the 1-cell stage, transcript levels of histone methyltransferases 
are high, demethylases levels are almost undetectable, and tri-methylation of lysine 27 is at its 
highest level. When the early porcine embryo reaches the 4-cell stage (time of genomic 
activation in the species) levels of histone methyltransferases are low, levels of demethylases 
are high, and levels of tri-methylation of lysine 27 in histone 3 have decreased (Gao et al., 
2010). 
2.1.1.3.1 Lysine (K)-specific demethylase 6B (KDM6B) 
Also known as the Jumonji Domain Containing 3, Jumonji Domain Containing protein 3, 
JmjC Domain-Containing protein 3, and Lysine demethylase 6B. KDM6B specifically 
demethylates lysine 27 in histone. Because its demethylase activity was first identified 
associated with the expression of genes of the HOX family, its activity has been related to the 
regulation of the homeotic development of the early embryo.  
The role of KDM6B has not been clearly established, but it has been demonstrated to 
have the capacity to remove repressive marks, add activating marks, and prevent the activity of 
Polycomb proteins by not prohibiting access to regulatory regions of genes associated with cell 
fate decisions (Agger et al., 2007). 
In both bovine and porcine models, early embryos show a progressive decrease in the 
level of H3K27me3, reaching the lowest levels by the time of genomic activation (Ross et al., 
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2008; Gao et al., 2010).  The expression of H3K27me3 demethylases UTX was undetectable at 
the 1-cell stage and had minimal levels at the 4-cell stage (the maternal-zygote transition point 
in the pig) with levels of KDM6B peaking at the 4-cell stage (Gao et al., 2010).  
2.1.2. Methylation of Arginine Residues 
Arginine methylation is a very well conserved mechanism through evolution (Wang et al., 
2001) and it has been associated with active transcription, using a mechanism similar to histone 
methylation, by modifying the interactions between chromatin and effector proteins. However, 
information about arginine methylation is limited and difficult to interpret since this modification 
is difficult to detect in vivo. Its synthesis and activity seems to be cyclical, and methyl-arginine 
binding proteins are yet to be identified (Lepikhov and Walter, 2004).  
Protein Arginine methyltransferases (PRMTs) catalyze the transfer of methyl groups 
from s-adenosyl-L-methionine (SAM) to the guanidine nitrogens of arginine residues. Arginine 
residues in histone proteins can be mono-methylated or di-methylated; the di-methylation can 
be symmetrical or asymmetrical. The enzymes that catalyze this process have been divided into 
two types, with the type I catalyzing the formation of asymmetric di-methyl arginine residues, 
whereas the type II enzyme catalyzes the formation of symmetric di-methyl arginine residues 
(Zhang and Reinberg, 2001).  
PRMT as a protein family has multiple target proteins, but at least two of its members 
have been identified to methylate arginine residues in histone proteins: PRMT1 and CARM1, 
also called PRMT4 (Zhang and Reinberg, 2001). What makes PRMTs particularly interesting is 
that they seem not to be exclusively histone methyltransferases. They appear to share their role 
of transcriptional regulators among other tasks. CARM1 methylates in vitro histone 3 at arginine 
2, 17, and 26, as well as members of the p160 family of co-activators of transcription (Chen et 
al., 1999). PRMT1 regulates the interferon signaling pathway (Abramovich et al., 1997), protein 
regulators of transcription such us STAT1 (signal transducers and activators of transcription) 
(Mowen et al., 2001), and Histone 4 at arginine 3 (Wang et al., 2001). The mechanisms by 
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which PRMT coordinates their dual regulation of transcription (regulating chromatin structure 
and regulating transcription activators) has yet to be elucidated.   
The role of PRMTs during embryo development is not clear (Wang et al., 2001). PRMT 
mutant mouse embryos fail to develop further than the blastocyst stage, suggesting an 
important role during early embryo development, but at a cellular level PRMTs are not required 
for cell survival. It is questionable if the main role of PRMT during early embryo development is 
actually associated with the methylation of histone tails or with its interaction with other nuclear 
proteins (Pawlak et al., 2000).  
Two enzymes have been described as active histone arginine methyltransferases: 
PRMT1 and CARM1. PRMT1 was first isolated and purified by Wang, et al. in 2001 and it is the 
most abundant H4-specific HMT. A 42-kD polypeptide, it has been proven to methylate H4R3 
both in vivo and in vitro (Wang et al., 2001). PRMT1 lacks any lysine methyltransferase activity, 
is inhibited by acetylation of lysine residues, and shows high affinity RNA binding proteins in 
vivo, but the significance and biological implications of these characteristics are poorly 
understood.  The other histone arginine methyltransferase, CARM1, has been associated with 
transcriptional activation (Chen et al., 1999).   
2.2. Histone Ubiquitination  
Ubiquitin is a 76 amino acid protein that can modify proteins by being transferred from 
the intermediary enzyme to lysine residues in the target protein. Substrates can be mono- or 
poly-ubiquitinated, with poly-ubiquitination being a frequent mark for protein degradation and 
mono-ubiquitination a mark for subsequent modifications in the target protein. Ubiquitination is a 
reversible modification; ubiquitin-specific proteases are responsible for removing this mark. 
Histone 2A is ubiquitinated at lysine 119 and histone 2B is ubiquitinated at lysine 120 by Rad6 




Ubiquitination of H2A has been associated with transcriptional silencing by recruiting 
chromatin modifying proteins such as members of the Polycomb repressive complex 1 or by 
being functionally coupled to methylation of other H3 lysines that regulate gene silencing 
(Baarends et al., 2005). Transcriptional repression due to stimulation of high-order chromatin 
formation has also been postulated (Weake and Workman, 2008).  
Ubiquitination of histone 2B regulates gene expression by participating in transcriptional 
activation after histone associated ubiquitin proteins interact with RNA polymerase II (Weake 
and Workman, 2008). It has also been proposed that H2B works as a check point at which RNA 
polymerase II pauses during early transcription elongation. H2B ubiquitination has also been 
described as an epigenetic regulator due to its interactions with other covalent modifications in 
histone residues. Specifically, it regulates the methylation of histone 3 at lysines 4 and 79, but 
not the methylation of histone 3 at lysine 36. 
Ubiquitination of H2B at lysine 123 is mediated by the enzyme Rad6, also known as 
ubiquitin-conjugating enzyme. The mutation of RAD6 induces a lack of methylation at lysines 4 
and 79, but does not alter the methylation at lysine 36. Therefore, it has been proposed that 
ubiquitination of H2B works as an epigenetic switch that marks subsequent epigenetic 
modifications (Briggs et al., 2002). However, mutations at lysine 79 do not interfere with the 
regulation of Lysine 4 by ubiquitination of H2B and vice versa, showing that the regulatory 
mechanism is unidirectional and independent from each other (Briggs et al., 2002). 
The regulatory mechanisms that use histone ubiquitination are still incompletely 
characterized; it is not clear why H2B is a mark associated with the transcribed region of most 
genes, but it only appears to have a regulatory role in a small subset of these genes. An 
alternative mechanism suggests that ubiquitination participates in transcriptional regulation 
indirectly, since ubiquitination of H2B has been reported as necessary for the demethylation of 
H3K4 and H3K79 in eukaryotes (Dover et al., 2002; Sun and Allis, 2002). It has also been 
reported that levels of H2B increase during cell differentiation processes and alterations in the 
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levels of ubiquitin-conjugating enzymes induce modification in the differentiation process of 
human or mice embryonic stem cells, but no clear mechanisms have been described yet (Fuchs 
et al., 2012; Karpiuk et al., 2012).  
2.3 Histone Acetylation 
Acetylation of histone tails regulates gene expression by modifying chromatin structure. 
In general, acetylation of histone tails correlates with the opening of chromatin structures, 
increasing the DNA accessibility for transcription factors resulting in an increase in gene 
expression (Vandel and Trouche, 2001; Zhang and Reinberg, 2001). The p300/CBP protein 
complex apparently has intrinsic histone acetyl transferase activity. But this protein complex is 
also associated with the transcriptional activation of several transcription factors (Giordano and 
Avantaggiati, 1999). Histone acetylation has the potential to link two different mechanisms of 
transcriptional regulation controlled by the same protein complex.  
The levels of histone acetylation in vivo are very dynamic; they are balanced out by two 
opposing sets of enzymes: histone acetyl transferases and histone deacetylase. They work 
antagonistically, but simultaneously lead to the changes in gene expression required by the cell 
to adjust to changing environments (Cheung et al., 2000). The easily reversible acetylation 
marks provide the cell with the means to respond quickly to changes in the environment by 
rapid changes in gene expression patterns (Shi and Whetstine, 2007). 
Many enzymes have been reported with histone acetyl transferase activity, most of them 
having specific affinity for lysine residues in H3 and H4 N-terminal tails. Gnc5 was the first 
family of histone acetyl transferase proteins to be identified (Brownell et al., 1996). It is highly 
conserved among eukaryote organisms. It seems that Gnc5 is recruited by the interaction 
between activator proteins and the promoter region of a specific cluster of genes (Lo et al., 
2000). After recruitment, Gnc5 acetylates histone proteins within the basal promoters of these 
genes, facilitating the access of transcription factors.  
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Histone acetylation of histone 3 at lysine 12 showed a dynamic pattern during bovine 
oocyte maturation with a strong signal at the GV and GVBD stages, and a marked decrease in 
MI and MII stages. This observation was constant regardless of the size of the follicle from 
which the oocyte was collected before maturing them in vitro (Racedo et al., 2009). 
2.4. Histone Phosphorylation 
There is an increase in phosphorylation of histone 1 during mitosis in eukaryote cells 
(Bradbury et al., 1973), and there is a site specific phosphorylation of core histone 3 at serine 10 
during mitosis in mammalian cells (Gurley et al., 1978). These two finding made scientists 
believe for a long time that there was a direct association between histone phosphorylation and 
chromatin condensation prior to mitosis in the cell cycle. However, it was later shown that 
neither histone 1 phosphorylation (Guo et al., 1995) nor histone 1 itself (Ohsumi et al., 1993) 
were necessary for mitotic chromosome condensation. Therefore, scientists have been very 
careful about postulating an association of causality between histone phosphorylation and 
chromatin condensation.  
Based on evidence that indicates that phosphorylation of serine 10 in histone 3 only 
occurs during mitosis in mammalian cells in vivo (Wei et al., 1999) have proposed two possible 
theories for the link between histone phosphorylation and chromatin condensation. Histone 
phosphorylation causes a transient decondensation of chromatin that facilitates the binding of 
chromatin condensing proteins to the DNA and/or the phosphorylated histone itself might act as 
a mark for chromatin condensation factors (Wei et al., 1999).  
However, phosphorylation brings a negative charge into the positively charged H3 amino 
terminus, reducing the interaction between H3 and DNA and theoretically inducing more 
decondensation than condensation of the chromatin structure. Furthermore, phosphorylation of 
H3S10 by Aurora B protein disrupts the interaction between H3K9 and HP1 when the cell enters 
the M phase of the cell cycle. This means that during interphase, HP1 can stay associated with 
tri-methylated H3K9. However, before mitosis takes place, HP1 and H3K9me3 must dissociate, 
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and the phosphorylation of H3S10 changes the affinity of H3K9 for HP1, allowing a cell cycle-
dependent dissociation of heterochromatic regions (Fischle et al., 2005).  
And the links between histone phosphorylation and the regulation of the cell cycle do not 
end there. Phosphorylation of histone 3 has been associated with the regulation of transcription 
of families of protein kinases involved in cell cycle regulation (Sassone-Corsi et al., 1999), with 
the transcriptional activation of mitogen-stimulated response genes, such as c-fos  and c-jun 
(Mahadevan et al., 1991), and with proteins of the MAP signaling pathway. All these interactions 
suggest an important role of the histone 3 phosphorylation in regulation of cell cycle, mitosis, 
cell proliferation, and cell differentiation.  
A second regulatory mechanism involving histone phosphorylation has been postulated 
based in the frequency that phosphorylation overlaps prior to post-translational modifications on 
the same histone tail.  A well-documented example is the interaction between the 
phosphorylation of serine 10 and the acetylation of lysine 14 in histone 3.  Gcn5, the histone 
acetylase, displays up to a 10-fold greater affinity for phosphorylated serine 10 in histone 3 as a 
substrate compared to the unmodified form of H3, and phosphorylation of serine 10 in histone 3 
has been functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14 (Lo et 
al., 2000). This type of interaction has been described as “dimodified status of histone tails” 
(Cheung et al., 2000). 
Based on this dimodified status of the histone 3 tail, some authors suggests that histone 
proteins might also follow the regulatory mechanisms described for other families of regulatory 
proteins, in which several modifications regulate different levels of enzymatic activity (Cheung et 
al., 2000). Other authors suggest that since covalent modifications work as interaction signals 
for effector proteins, the presence of more than one modification simultaneously might serve as 
a highly specific marker for regulatory proteins (Mahadevan et al., 1991). However, the 
transcription associated phosphorylation of histone 3 only occurs in discrete areas of the 
genome; it means that the acetylation of lysine 14 also occurs independently of phosphorylation 
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and that single modifications are more the rule than the exception. At this point, the 
understanding of the mechanism that regulate histone modifications, as well as the 
consequences of such modifications, are only partially understood. More effort and research is 




















DIFFERENCES IN LEVELS OF HISTONE METHYLTRANSFERASE 
TRANSCRIPTS BETWEEN IMMATURE, IN VITRO MATURED, AND  
IN VIVO MATURED BOVINE CUMULUS CELLS AND OOCYTES 
 
3.1. Introduction 
 The difference in developmental competence between in vitro matured oocytes and in 
vivo matured oocytes has been well established, with in vivo matured oocytes reaching higher 
rates of embryo development than their in vitro matured counterparts. It has also been 
established that the different phenotypes of oocytes matured in vivo compared with oocytes 
matured in vitro offers the possibility to compare their mRNA content (Labrecque and Sirard, 
2014). During the experiments described in this chapter, the difference in developmental 
competence between immature oocytes, in vitro matured oocytes and in vivo matured oocytes 
is used as a system to explore possible differences in the accumulation of transcripts during the 
final maturation of the oocyte.  
 Soon after fertilization the gametes must undergo extensive epigenetic reprogramming 
to achieve the epigenetic landscape required to establish the totipotent stage characteristic of 
early embryo development. However, genomic activation (GA) does not occur in the bovine 
embryo until the eight- to 16-cell stages (day 2.5 – 3 after fertilization), suggesting that the 
proteins required for the epigenetic reprogramming prior to the eight-cell stage cannot be 
synthetized by the early embryo and must be provided in the form of mRNAs by the oocyte. 
These mRNAs are synthetized and accumulated during the final maturation of the oocyte. The 
experiments in this chapter conduct transcriptome analysis of mRNAs accumulated during the 
final stages of oocyte maturation that code for proteins associated with epigenetic 
reprogramming.  
The post-translational modification of histone proteins has been identified as one of the 
key regulatory mechanisms involved in epigenetic reprogramming.  Histone methyltransferase 
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proteins have the potential to modify chromatin structure and, therefore, regulate gene 
expression. This regulation has been proven to be critical in the early embryo since genes 
leading to early totipotent development (which remain silent in most somatic cells and gametes) 
must be actively expressed, whereas every other gene that is not critical for developmental 
potential must be silenced. The experiments described in this chapter study transcripts of 
enzymes responsible for the post-translational modification of histones.   
The preponderant role that cumulus cells play during oocyte maturation has been well 
established. Bilateral communication exists between the oocyte and the surrounding cumulus 
cell which includes paracrine signaling and the transfer of small molecules via gap junctions. 
Cumulus cells even regulate the beginning of nuclear maturation by constantly supplying the 
oocyte with cyclic adenosine monophosphate (cAMP), which prevents the enzymatic cascades 
responsible for resumption of meiosis. It has been proposed that it is the rupture of the link 
between the cumulus cells and the oocyte which causes the decline in the levels of cAMP in the 
ooplasm, leading to the resumption of meiosis. Even more, recent research suggests that during 
the period of transcriptional incompetence due to the resumption of meiosis, cumulus cells 
transfer critical mRNAs required for embryonic development to the oocyte (Macaulay et al., 
2014). During the experiments presented in this chapter, cumulus-oocyte complexes were used 
for transcriptome analysis, which was additionally performed in oocytes and cumulus cells 
separately. 
This chapter describes three experiments using the difference in developmental 
competence between immature oocytes, in vitro matured oocytes, and in vivo matured oocytes 
as a system to research the accumulation of mRNAs transcripts during the final stages of 
oocyte maturation. These experiments centered on mRNAs that are involved in epigenetic 
reprograming in the early embryo by selecting four transcripts, which code for three histone 
methyltransferases and one histone demethylase for analysis. These transcripts were studied in 
bovine cumulus-oocyte complexes, denuded oocytes and biopsies of cumulus cells.  
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3.2. Materials and Methods 
3.2.1. Animal husbandry  
 Experimental procedures in this study were approved by the Louisiana State University 
Animal Care and Use Committee and conducted at the Louisiana State University Agricultural 
Center Reproductive Biology Laboratory (RBC) - Embryo Biotechnology Laboratory (EBL) in 
Saint Gabriel, Louisiana from August 2012 through July 2013.  
Non lacting crossbred (Angus x Red Angus x Brangus) cows (n=40) 4 to 7 years of age, 
maintained as the experimental physiology herd at the LSU RBC, were used throughout the 
course of this study. The cows displayed regular estrous cycles, were all in moderate to good 
body condition, and were maintained on pastures planted with Bermudagrass (Cynodon 
dactylon) and White clover (Trifolium repens). Hay was provided ad libitum during the winter 
season.  
  The Louisiana State University RBC is located in South Louisiana. It is situated at 30˚16’ 
north latitude, 91˚06’ west longitude, and has a subtropical climate. The elevation is nine meters 
above the sea level, the average annual precipitation is 150 meters, and the average day length 
is 12.6 hours. 
3.2.2. Experimental design 
 Three experiments were conducted to investigate the relative abundance of histone 
methyltransferase transcripts in bovine cumulus cells and oocytes: 
 Experiment one: Cumulus-oocyte complexes were used to investigate differences in 
transcripts for histone methyltransferases ASH1L, EHMT2, SUV39H1 and KDM6B 
between immature cumulus-oocyte complexes, in vitro matured cumulus-oocyte 
complexes and in vivo matured cumulus-oocyte complexes.  
 Experiment two: Oocytes were used to investigate differences in transcripts for histone 
methyltransferases ASH1L, EHMT2, SUV39H1 and KDM6B between immature oocytes, 
in vitro matured oocytes and in vivo matured oocytes.  
28 
 
 Experiment three: Samples of cumulus cells were used to investigate differences in 
transcripts for histone methyltransferases ASH1L, EHMT2, SUV39H1 and KDM6B 
between immature cumulus cells, in vitro matured cumulus cells and in vivo matured 
cumulus cells.  
For all three experiments presented in this chapter, the experimental unit was defined as 
the oocyte and the sampling unit was defined as the oocyte. In order to study the possible 
differences in gene expression between cumulus cells and oocytes, three experimental 
treatments were defined for each experiment: 
 Treatment one: Immature cumulus cells and/or oocytes were used for transcriptome 
analysis after transvaginal ultrasound guided aspiration when still at a germinal vesicle 
stage. 
 Treatment two: In vitro matured cumulus cells and/or oocytes were used for 
transcriptome analysis after transvaginal ultrasound guided aspiration of oocytes at the 
germinal vesicle stage and maturation in vitro until arrested at the metaphase II stage. 
 Treatment three: In vivo matured cumulus cells and/or oocytes were used for 
transcriptome analysis after in vivo maturation and transvaginal ultrasound guided 
aspiration when at a metaphase II stage. 
3.2.3. Synchronization for collection of cumulus-oocyte complexes  
 Two synchronization protocols were used for these experiments. The first was used to 
collect immature oocytes (germinal vesicle stage) and the second was used to collect in vivo 
matured oocytes (metaphase II stage). These synchronization protocols are based on those 
described by Rizos (Rizos et al., 2002) and used by others to collect both in vitro matured and in 
vivo matured cumulus-oocyte complexes for transcriptome analysis (Tesfaye et al., 2009; Assidi 
et al., 2013; Spencer et al., 2013).   
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 Synchronization protocol one was used to retrieve immature oocytes for use in 
experimental treatments one and two. An outline of this protocol is presented in Figure 3.1. A 
controlled internal release device with progesterone (Easi-BreedTM CIDR cattle insert®, Zoetis 
laboratories) was placed intravaginally for ten days and prostaglandin F2α (PGF2α, 25 mg of 
dinoprost tromethamine, Lutalize®, single dose, intramuscular) was given the day of CIDR 
removal. Cows were observed for signs of estrous behavior 48 to 72 hours after the 
administration of PGF2α, and cows displaying standing estrus were identified and recorded. 
Cows that failed to display estrus during the observation period were also identified, but they 
were not removed from the experimental group. Eight days after starting estrus, growth of all 
dominant follicles was impaired using an ultrasound-guided needle. Then, four days after 
dominant follicle removal (DFR), transvaginal ultrasound-guided aspiration of follicles was 
performed.  
Synchronization protocol two was similar to protocol one; an outline of the protocol is 
presented in Figure 3.2. A CIDR in combination with PGF2α was used to synchronize estrus.  
Dominant follicle removal was performed eight days after standing estrus and PGF2α was 
administered four days after DFR. Cows displaying estrous behavior were given PGF2α and 
Gonadotropin releasing hormone (GnRH, 100 µg of Gonadorelin hydrochloride, Factrel®, single 
dose) intramuscular 48 hours later. Transvaginal ultrasound-guided aspiration of oocytes was 
performed 12 hours after the administration of GnRH. 
Protocol one was used in ten cows, whereas protocol two was used in 40 animals. There 
was an interval of, at least, 40 days between the end of protocol one and the beginning of 
protocol two. When environmental factors, such as high temperatures during the summer, 
affected the quality of the oocytes, collections were suspended until conditions returned to 
normal and cows recovered their cyclicity. Cows used in protocol one were selected randomly 







Figure 3.1.  Synchronization protocol for transvaginal ultrasound-guided aspiration of immature oocytes.  CIDR is controlled 
internal drug release device; PGF2α is prostaglandin F 2 alpha; DFR is dominant follicle removal; TUGA is transvaginal 
ultrasound-guided aspiration. 
CIDR 







Figure 3.2.  Synchronization protocol for transvaginal ultrasound-guided aspiration of in vivo matured oocytes.  CIDR is 
controlled internal drug release device; PGF2α is Prostaglandin F 2 alpha; DFR is dominant follicle removal; GnRH is 
Gonadotropin Releasing Hormone, TUGA is transvaginal ultrasound-guided aspiration. PM indicates that treatments were 


















3.2.4. Collection of cumulus-oocyte complexes  
 Cumulus-oocyte complexes (COCs) were collected by transvaginal ultrasound-guided 
aspiration (TUGA) of antral follicles. Equipment and materials used for TUGA are presented in 
Appendix C. Cows were briefly restrained in a holding chute and given an epidural injection of 
six mL of lidocaine 2% (lidocaine hydrochloride, VETone® pharmaceuticals). A 7.5 MHz 
ultrasound transducer was used trans-vaginally as the ovaries were manipulated trans-rectally.  
The image provided by the ultrasound was used by the technician to identify the follicles and 
direct an 18g X 88.9mm needle to aspirate the follicular contents. The needle was connected by 
tubing to a bovine embryo filter with a 75 micron membrane (EmComTM Filter). A vacuum pump 
was connected to the filter to apply negative pressure, enhancing the recovery of follicular 
contents. 
Oocyte collection medium (OCM) used to lubricate the surfaces with the potential to be 
in contact with the follicular contents and provide an isotonic, isothermal environment for the 
oocytes within the collection system. OCM used was Dulbecco’s phosphate-buffered saline 10X 
(DPBS, Sigma, D1283) diluted to a working concentration (1X) supplemented with 1% calf 
serum and 10 IU/mL of heparin (Heparin sodium, Sagent® pharmaceuticals). Detailed 
information about the OCM can be found in Appendix B. Immediately following collection, 
oocytes were transferred to a gridded dish and stereoscopic microscopes were used to search, 
rinse and collect cumulus-oocyte complexes. 
3.2.5. Sample evaluation and freezing  
The evaluation protocol was the same for all three treatments in all three experiments. 
Cumulus-oocyte complexes which were expected to be at germinal vesicle stage were 
evaluated based on the homogeny of the ooplasm and the presence of several layers of 
compact cumulus cells. Cumulus-oocyte complexes expected to be at the metaphase II stage 




Samples for all experiments and treatments were placed in 1.8 mL centrifuge tubes in a 
volume of less than 5 µL of DPBS containing 0.1% polyvinyl alcohol (PVA) and stored at -80°C 
for later RNA analysis. 
3.2.6. Sample processing  
The processing of samples was different between experiments because Experiment one 
used cumulus-oocytes complexes (COCs), Experiment two used oocytes, and Experiment three 
used cumulus cells. In Experiment one cumulus-oocyte complexes were used as samples 
without any further processing. For Experiment three, a small group of cumulus cells were 
removed from the outer layers of the cumulus to be used as the sample. For Experiment two, 
cumulus cells of the COCs used in Experiment three were removed using a 0.1% hyaluronidase 
solution (Sigma® H-3506).  COCs were held in hyaluronidase solution at 39°C for seven 
minutes and then vortexed for ten minutes. The resulting denuded oocytes were used as the 
sample.   
3.2.7. In vitro maturation of cumulus-oocyte complexes 
 Treatment two of all three experiments required in vitro maturation of the cumulus-
oocyte complexes (COCs). The protocol for in vitro oocyte maturation can be found in Appendix 
A, the formulation for the maturation medium can be found in Appendix B, and a list of the 
equipment and materials used during in vitro maturation are presented in Appendix C. 
Immediately after collection and evaluation, COCs assigned to Treatment two were washed four 
times through standard maturation medium and transferred into 35 µL drops of maturation 
medium covered with 570 µL of mineral oil and incubated in 5% CO2 at 39˚ C for 22 hours. 
Maturation medium was tissue culture medium 199 supplemented with 10% fetal bovine serum, 
0.2 mM sodium pyruvate, 2 mM glutamine, 5 µm/mL of FSH and 1% penicillin/streptomycin. 
3.2.8. Primer selection and validation 
 Three genes coding for three histone methyltransferases (ASH1L, EHMT2, and 
SUV39H1) and one gene coding for a histone demethylase (KDM6B) were selected as genes of 
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interest, and two housekeeping genes (Poly A polymerase and GADPH) were selected as 
reference genes. Primers (forward and reverse) for each gene were acquired from Invitrogen™. 
Primers accession numbers, sequences and product size can be found in table 3.1.  
RNA was extracted from ovarian tissue and reverse transcriptase PCR was used to 
produce an initial calibrator. The main characteristic of this initial calibrator is to contain the DNA 
sequences for the four genes of interest and the two housekeeping genes. The initial calibrator 
was used to produce purified PCR product for each gene, which was used to determine the 
optimal annealing temperature for each set of primers, to corroborate that each set of primers 
was amplifying a single product, and to spike the initial calibrator with purified PCR product from 
each gene to produce a final calibrator. This final calibrator was used to generate the QPCR 
standard curves for each gene, and as a reference positive control in each QPRC reaction 
performed in the samples.  
Basic PCR reactions consisted of 25 µL JumpstartTM Red taq® Ready Mix (P0982, 
Sigma), 2 µL of the forward primer, 2 µL of the reverse primer, 10 µL of DNA from a calibrator, 
and 11 µL of dH2O for a total of 50 µL. The thermocycler was programmed for four steps. Step 
one was 94°C for two minutes; step two was 35 cycles of 30 seconds at 94°C, 30 seconds at 
the specific annealing temperature of each set of primers, and one minute at 72°C for 
elongation; step three was one cycle of five minutes at 72°C for final extension and step four 
was holding the PCR product at 4°C until removed from the thermocycler. 
 Real time PCR reactions consisted of 4 µL of calibrator, 10 µL of SsoFast™ EvaGreen® 
supermix (172-5200, Sigma), 10 µmol of forward primer, 10 µmol of reverse primer and 4 µL of 
nuclease-free water. The thermocycler was programmed for three steps. The first step was one 
minute at 95 ˚C; the second step was 40 cycles of 30 seconds at 95 ˚C and 30 seconds at 61°C 
and the third step consisted of 68 cycles with 0.5°C increases every ten seconds, starting at 
















F   5’ -ACCTCCTCCATCGCCTTC 
R   5’ –TGTGCTCAACCATCCAACC 
215 
EHMT2 NM_001206263 
F   5’ -CTCTACTATGATTCCTACTCTG 
R   5’ –CATCTTCCTCTTCTTCTTCC 
163 
SUV39H1 NM_001046264 
F   5’ -ACTAAGCGACTTCACTTCAC 
R   5’ -GGCACCTCCTCAGTATCC 
216 
KDM6B XM_003587412 
F   5’ -CCATCAAGAGAACAACAAC 
R   5’ -GAAGCATAGAGGTCATCC 
174 
Poly A X63436 
F   5’ -AAGCAACTCCATCAACTACTG- 3’ 
R   5’ -ACGGACTGGTCTTCATAGC- 3’ 
169 
GAPDH U85042 
F   5’ -CCTTCATTGACCTTCACTACATGGTCTA- 3’ 
R   5’ -TGGAAGATGGTGATGGCCTTTCCAT- 3’ 
127 
1ASH1L: Bos taurus absent, small, or homeotic-like Drosophila, mRNA; EHMT2: Bos taurus euchromatic histone-lysine N-
methyltransferase 2, mRNA; SUV31: Bos taurus suppressor of variegation 3-9 homologue 1, mRNA; KDM6B: PREDICTED: Bos 
taurus lysine (K)-Specific Demethylase 6B, mRNA; Poly A: Bos taurus poly( A) polymerase (Poly A)- reference gene; GADPH: Bos 




3.2.9. RNA extraction 
 Total RNA was extracted using RNeasy® Plus Micro Kit (74034, Qiagen®) following the 
manufacturer recommendations of the fabricant. A copy of the RNA extraction protocol can be 
found in Appendix A. Briefly, lysing buffer was added to frozen samples to prevent mRNA 
losses during thawing, and an affinity column was used to remove the genomic DNA; a second 
affinity membrane is used to retain the RNA while organic solvents remove any remaining lipids 
and proteins from the sample. Total RNA in each sample was eluted in 15 µL of RNase-free 
water and used immediately for reverse-transcriptase PCR.   
3.2.10. Complementary DNA 
 After mRNA isolation, each sample was processed with Bio-Rad iScriptTM cDNA 
Synthesis Kit (170-8891, Bio-Rad laboratories) according to the manufacturer 
recommendations. The iScript reverse transcriptase uses a blend of oligo-di-nucleotides and 
random hexamer primers to transcribe mRNA into cDNA. A complete copy of the RT-PCR 
protocol is in Appendix A. 
 The protocol used in the thermocycler to synthesize complementary DNA consisted of 
four steps. In the first step, the PCR reaction is heated to 25˚C for five minutes to activate the 
enzyme. In step two, the PCR reaction is heated to 42˚C for 30 minutes to allow the activity of 
the reverse transcriptase polymerase. Step three heated the PCR reaction to 85˚C to denature 
the enzyme and finish the reaction. The last step held the PCR product at 4˚C until the reactions 
were removed from the thermocycler. 
3.2.11. Quantitative real-time PCR 
 Transcriptome levels for histone methyltransferases were quantified using real-time 
PCR. The protocol used can be found in detail in Appendix A. Briefly, 10 µL of SsoFastTM 
EvaGreen® Supermix, 2 µL of forward primer, 2 µL of reverse primer, 4 µL of cDNA from 
samples and 2 µL of dH2O were used per reaction. SsoFast
TM was chosen because of its high 
efficiency, sensitivity, and strong fluorescent signal. 
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 Thermocycler was programed to three steps. Step one was set to 95˚C for one minute, 
step two was selected to be 40 cycles of 95˚C for 5 seconds followed for 30 seconds at 61˚C, 
and step three was set to perform the melting curve with increments of 0.5˚C every ten seconds 
starting at 61˚C and finishing when reaching 95˚C. 
Q-PCR analysis was performed for two housekeeping genes (Poly A polymerase and 
GADPH) in each sample. Housekeeping genes were selected based on previous experiences at 
the lab. The geometrical mean was used as the “reference values for the housekeeping gene” 
to normalize the QPCR values of the samples for the four genes of interest.  
 The 2-ΔΔCT method was used to normalize the CT value of the samples. This method 
uses a two-step process to normalize Q-qPCR data in a semi-quantitative analysis. First, data 
were normalized against the reference value of the housekeeping genes within the same 
sample. The second normalization compares the difference in threshold values from the first 
step against the reference value, called the calibrator, which was a known positive control that 
remains constant for every PCR run of every gene in all experiments.  
3.2.12. Statistical Analysis 
Values of relative abundance of transcripts were calculated using the “Delta Delta Ct” 
method. After testing for normality (Kolmogorov-Smirnov test), a one-way ANOVA followed by 
pair-wise comparisons using Tukey’s test were performed using SigmaStat® Statistical 
Software (version 3.5). Differences of p < 0.05 were considered to be significant.  
3.3. Results  
3.3.1. Experiment One 
 Ten cows were synchronized following protocol one and 73 cumulus-oocyte complexes 
were recovered, yielding an average of 7.3 immature cumulus-oocyte complexes per cow. 
Morphological selection was used to select 64 cumulus-oocyte complexes. Half of these 
cumulus-oocyte complexes (n=32) were randomly selected to be matured in vitro. The 
remaining half was immediately frozen in two oocytes per sample, resulting in 16 samples of 
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immature cumulus-oocyte complexes. After in vitro maturation was completed on the first set of 
cumulus-oocyte complexes, these were also frozen randomly in two cumulus-oocyte complexes 
per sample (16 samples total) and stored at -80°C until further processing. 
Synchronization protocol two was used 40 days later in 40 cows, and 19 in vivo matured 
cumulus-oocyte complexes were recovered, yielding an average of 0.75 cumulus-oocyte 
complexes per cow.  A total of 16 cumulus-oocyte complexes were selected based on the 
expansion of the cumulus cells and the homogeny of the ooplasm, and these were frozen one 
COC per sample (16 samples total).  
The analysis of variance for the treatments (immature oocyte, in vitro matured oocytes 
and in vivo matured oocytes) when the transcriptome from cumulus-oocyte complexes was 
analyzed showed that there was no difference between any of the treatments for the genes 
ASH1L, SUV39H1, and KDM6B (p = 0.882, p = 0.510, p = 0.068, respectively). The powers of 
the performed tests were 0.049, 0.049 and 0.354 respectively. 
There was a difference (p = 0.005) between the treatments for the EHMT2 gene. There 
was an increase in the number of transcripts for the EHMT2 gene in in vitro matured oocyte 
treatment compared with  the in vivo matured treatment (p = 0.007) and immature treatment (p 
= 0.021). There was no difference between the in vivo and the immature treatments (p = 0.907). 
The power of this test was 0.798.The relative abundance of transcripts for the ASH1L, 
SUV39H1, KDM6B and EHMT2 for each sample in each treatment in Experiment one can be 
found in tables 3.2, 3.4, 3.6 and 3.8, respectively.   
The tables detailing the ANOVA analysis comparing the immature, in vitro matured, and 
in vivo matured treatments for the ASH1L, SUV39H1, KDM6B and EHMT2 genes in Experiment 
one can be found in the tables 3.3, 3.5, 3.7 and 3.9, respectively. The pair-wise comparisons 
(Tukey’s test) between treatments for the EHMT2 gene in Experiment one can be found in table 
3.10. Histograms comparing the relative abundance of transcript for ASH1L, SUV39H1, KDM6B 
and EHMT2 genes can be found in figure 3.3. 
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Table 3.2 Relative expression for the ASH1L gene in Experiment one 
Treatment Immature COCs In vitro matured COCs In vivo matured COCs 
Calibrator 1.000 1.000 1.000 
Sample 1 0.022 0.115 0.011 
Sample 2 0.034 0.543 9.396 
Sample 3 0.012 0.034 0.010 
Sample 4 0.050 0.074 0.038 
Sample 5 0.346 0.037 0.035 
Sample 6 0.012 0.352 0.087 
Sample 7 0.113 0.060 0.056 
Sample 8 0.014 0.014 0.022 
Sample 9 0.061 0.036 0.532 
Sample 10 0.035 0.051 0.108 
Sample 11 0.029 0.193 0.031 
Sample 12 0.019 0.248 0.012 
Sample 13 0.484 0.749 0.038 
Sample 14 0.011 1.041 0.185 
Sample 15 8.477 0.370 0.060 
Sample 16 0.020 1.824 0.005 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
Table 3.3 ANOVA analysis for the ASH1L gene in Experiment one 
Treatment N Missing Mean Std Dev SEM 
Immature COCs 16 0 0.609 2.103 0.526 
In vitro matured COCs 16 0 0.359 0.409 0.122 
In vivo matured COCs 16 0 0.664 2.332 0.583 
 
Source of Variation DF SS MS F P 
Between groups 2 0.846 0.423 0.126 0.882 
Residual 45 151.484 3.366   





Table 3.4 Relative expression for the SUV39H1 gene in Experiment one 
Treatment Immature COCs In vitro matured COCs In vivo matured COCs 
Calibrator 1.000 1.000 1.000 
Sample 1 0.681 0.299 0.076 
Sample 2 13.164 1.769 0.142 
Sample 3 0.325 0.269 0.071 
Sample 4 1.325 0.269 0.093 
Sample 5 3.524 0.815 0.113 
Sample 6 0.471 1.624 0.094 
Sample 7 0.248 2.694 0.110 
Sample 8 3.101 0.233 0.074 
Sample 9 0.049 1.173 6.631 
Sample 10 0.030 1.839 0.433 
Sample 11 0.058 0.645 0.572 
Sample 12 0.096 0.403 0.562 
Sample 13 0.451 1.848 1.150 
Sample 14 0.028 0.104 0.242 
Sample 15 0.424 17.101 0.391 
Sample 16 0.588 0.552 0.228 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.5 ANOVA analysis for the SUV39H1 gene in Experiment one 
Treatment n Missing Mean Std Dev SEM 
Immature COCs 16 0 1.535 3.276 0.819 
In vitro matured COCs 16 0 1.977 4.106 1.027 
In vivo matured COCs 16 0 0.686 1.611 0.403 
 
Source of Variation DF SS MS F P 
Between groups 2 13.769 6.884 0.684 0.510 
Residual 45 452.830 10.063   




Table 3.6 Relative expression for the KDM6B gene in Experiment one 
Treatment Immature COCs In vitro matured COCs In vivo matured COCs 
Calibrator 1.000 1.000 1.000 
Sample 1 0.539 0.298 0.103 
Sample 2 2.890 12.972 0.481 
Sample 3 2.979 3.070 0.144 
Sample 4 4.372 0.951 0.077 
Sample 5 4.552 1.548 0.144 
Sample 6 2.319 3.119 0.231 
Sample 7 0.704 1.313 2.755 
Sample 8 4.802 0.588 0.302 
Sample 9 0.158 0.612 0.482 
Sample 10 0.495 1.209 0.767 
Sample 11 0.625 2.220 0.138 
Sample 12 0.140 0.632 0.152 
Sample 13 0.404 441.252 0.198 
Sample 14 0.223 2.345 0.243 
Sample 15 1.049 129.660 4.032 
Sample 16 1.137 1.018 0.068 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.7 ANOVA analysis for the KDM6B gene in Experiment one 
Treatment n Missing Mean Std Dev SEM 
Immature COCs 16 0 1.712 1.687 0.422 
In vitro matured COCs 16 3 1.455 0.947 0.263 
In vivo matured COCs 16 0 0.645 1.113 0.278 
 
Source of Variation DF SS MS F P 
Between groups 2 9.817 4.909 2.861 0.068 
Residual 42 72.048 1.715   





Table 3.8 Relative expression for the EHMT2 gene in Experiment one 
Treatment Immature COCs In vitro matured COCs In vivo matured COCs 
Calibrator 1.000 1.000 1.000 
Sample 1 0.005 0.099 0.018 
Sample 2 0.011 1.172 0.018 
Sample 3 0.011 0.155 0.004 
Sample 4 0.252 0.673 0.003 
Sample 5 0.057 1.188 0.007 
Sample 6 0.008 1.543 0.012 
Sample 7 0.166 1.463 0.014 
Sample 8 0.018 0.588 0.002 
Sample 9 0.100 2.062 0.485 
Sample 10 0.258 0.281 0.225 
Sample 11 0.144 0.092 0.129 
Sample 12 0.245 0.055 0.111 
Sample 13 0.782 0.032 0.163 
Sample 14 0.093 0.135 0.068 
Sample 15 0.655 4.645 0.110 
Sample 16 0.309 0.033 0.058 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.9 ANOVA analysis for the EHMT2 gene in Experiment one 
Treatment n Missing Mean Std Dev SEM 
Immature COCs 16 0 0.195 0.230 0.057 
In vitro matured COCs 16 0 0.888 1.196 0.299 
In vivo matured COCs 16 0 0.089 0.125 0.031 
 
Source of Variation DF SS MS F P 
Between groups 2 6.034 3.017 6.042 0.005 
Residual 45 22.473 0.499   




Table 3.10 Pair-wise comparisons (Tukey’s test) for the EHMT2 gene in Experiment one 
Comparison Diff of means p q P p < 0.050 
In vitro vs. in vivo 0.799 3 4.525 0.007 Yes 
In vitro vs. immature 0.694 3 3.927 0.021 Yes 





Figure 3.3 Relative expression of histone methyltransferase transcripts in cumulus-oocyte 


























































































































3.3.2. Experiment Two 
 Ten cows were synchronized following protocol one and 59 cumulus-oocyte complexes 
were recovered, yielding an average of 5.9 immature cumulus-oocyte complexes per cow. 
Morphological selection was used to select 28 cumulus-oocyte complexes with enough layers of 
cumulus cells to allow for a biopsy of the cumulus cells. 14 cumulus-oocyte complexes were 
randomly selected, the biopsy of the cumulus cells was performed, and the cumulus cells were 
saved for use in Experiment three.  The remaining cumulus cells were removed using a 
hyaluronidase solution, and the denuded immature oocytes were frozen in a 1.8 mL centrifuge 
tube (two per sample) and stored at -80°C for further processing. The remaining 14 cumulus-
oocyte complexes were matured in vitro and then a biopsy of the cumulus cells was performed.  
Remaining cumulus cells were once again removed using hyaluronidase and the denuded in 
vitro matured oocytes were frozen and stored at -80°C for further processing. Cumulus cell 
biopsies from the in vitro matured oocytes were also saved to be used in Experiment three.  
Synchronization protocol two was started 40 days later in 40 cows. 12 in vivo matured 
oocytes were recovered, yielding 0.3 cumulus-oocyte complexes per cow.  Seven oocytes with 
evidence of cumulus cell expansion were selected and a biopsy of the cumulus cells was 
performed. Cumulus cells were saved to be used in Experiment three, then the oocytes were 
denuded using hyaluronidase and frozen using one oocyte per sample (7 samples total).  
No difference was found for EHMT2, SUV39H1, KDM6B genes (p = 0.614, p = 0.320, 
and p = 0.178, respectively). There was a difference (p < 0.001) for the ASH1L gene between 
treatments.  There was an increase in gene expression of the ASH1L gene in oocytes in the in 
vitro matured treatment compared with the in vivo matured treatment (p < 0.001), and the 
immature treatment (p < 0.001). There was no difference between the in vivo and the immature 
treatments (p = 0.453). The power of the ANOVA tests performed on the ASH1L, EHMT2, 




The relative abundance of transcripts for the ASH1L, SUV39H1, KDM6B and EHMT2 for 
each sample in each treatment in Experiment two can be found in tables 3.11, 3.14, 3.16 and 
3.18, respectively.  The tables detailing the ANOVA analysis comparing the immature, in vitro 
matured, and in vivo matured treatments for the ASH1L, SUV39H1, KDM6B and EHMT2 genes 
in Experiment two can be found in the tables 3.12, 3.15, 3.17 and 3.19, respectively. The pair-
wise comparisons (Tukey’s test) between treatments for the EHMT2 gene in Experiment one 
can be found in table 3.13. Histograms comparing the relative abundance of transcript for 
ASH1L, SUV39H1, KDM6B and EHMT2 genes can be found in figure 3.4. 
Table 3.11 Relative expression for the ASH1L gene in Experiment two 
Treatment Immature oocytes In vitro matured oocytes In vivo matured oocytes 
Calibrator 1.000 1.000 1.000 
Sample 1 0.005 0.997 0.008 
Sample 2 0.118 0.922 0.002 
Sample 3 0.005 0.997 0.009 
Sample 4 0.004 0.997 0.002 
Sample 5 0.005 0.996 0.003 
Sample 6 0.003 0.998 0.019 
Sample 7 0.728 0.604 0.011 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
Table 3.12 ANOVA analysis for the ASH1L gene in Experiment two 
Treatment n Missing Mean Std Dev SEM 
Immature oocytes 7 0 0.124 0.270 0.102 
In vitro matured oocytes 7 0 0.930 0.147 0.055 
In vivo matured oocytes 7 0 0.008 0.006 0.002 
 
Source of Variation DF SS MS F P 
Between groups 2 3.533 1.766 56.289 <0.001 
Residual 18 0.565 0.031   
Total 20 4.097    
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Table 3.13 Pair-wise comparisons (Tukey’s test) for the ASH1L gene in Experiment two 
Comparison Diff of means p q P p < 0.050 
In vitro vs. in vivo 0.922 3 13.775 <0.001 Yes 
In vitro vs. immature 0.806 3 12.040 <0.001 Yes 
Immature vs. in vivo 0.116 3 1.735 0.453 No 
 
 
Table 3.14 Relative expression for the EHMT2 gene in Experiment two 
Treatment Immature oocytes In vitro matured oocytes In vivo matured oocytes 
Calibrator 1.000 1.000 1.000 
Sample 1 0.050 0.029 0.012 
Sample 2 0.098 0.040 0.053 
Sample 3 0.035 0.024 0.019 
Sample 4 0.071 0.049 0.017 
Sample 5 0.065 0.250 0.051 
Sample 6 0.118 0.181 0.293 
Sample 7 0.018 0.210 0.231 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.15 ANOVA analysis for the EHMT2 gene in Experiment two 
Treatment n Missing Mean Std Dev SEM 
Immature oocytes 7 0 0.065 0.035 0.013 
In vitro matured oocytes 7 0 0.112 0.097 0.037 
In vivo matured oocytes 7 0 0.097 0.116 0.044 
 
Source of Variation DF SS MS F P 
Between groups 2 0.008 0.004 0.502 0.614 
Residual 18 0.144 0.008   





Table 3.16 Relative expression for the SUV39H1 gene in Experiment two 
Treatment Immature oocytes In vitro matured oocytes In vivo matured oocytes 
Sample 1 0.135 0.035 0.055 
Sample 2 0.065 0.032 0.074 
Sample 3 0.034 0.054 0.139 
Sample 4 0.097 0.064 0.025 
Sample 5 0.172 1.693 0.105 
Sample 6 0.068 0.604 0.127 
Sample 7 0.031 0.228 0.635 
Calibrator = positive control used to normalize QPCR values between samples. 
 
Table 3.17 ANOVA analysis for the SUV39H1 gene in Experiment two 
Treatment n Missing Mean Std Dev SEM 
Immature oocytes 7 0 0.086 0.052 0.020 
In vitro matured oocytes 7 0 0.337 0.612 0.231 
In vivo matured oocytes 7 0 0.166 0.211 0.080 
Source of Variation DF SS MS F P 
Between groups 2 0.341 0.170 1.215 0.320 
Residual 18 2.527 0.140   
Total 20 2.868    
 
 
Table 3.18 Relative expression for the KDM6B gene in Experiment two 
Treatment Immature oocytes In vitro matured oocytes In vivo matured oocytes 
Sample 1 0.008 0.008 0.021 
Sample 2 0.013 0.009 0.004 
Sample 3 0.019 0.004 0.001 
Sample 4 0.012 0.012 0.016 
Sample 5 0.011 0.086 ------- 
Sample 6 0.015 0.023 0.015 
Sample 7 0.005 0.211 0.005 




Table 3.19 ANOVA analysis for the KDM6B gene in Experiment two 
Treatment n Missing Mean Std Dev SEM 
Immature oocytes 7 0 0.012 0.005 0.002 
In vitro matured oocytes 7 0 0.051 0.076 0.029 
In vivo matured oocytes 7 0 0.009 0.008 0.003 
 
Source of Variation DF SS MS F P 
Between groups 2 13.769 6.884 0.684 0.510 
Residual 45 452.830 10.063   
Total 47 466.598    
 
3.3.3. Experiment Three 
 Ten cows were synchronized following protocol one and 59 cumulus-oocyte complexes 
were recovered, yielding an average of 5.9 immature cumulus-oocyte complexes per cow. 
Morphological selection was used to select 28 cumulus-oocyte complexes with enough layers of 
cumulus cells to allow for a biopsy of the cumulus cells. 14 cumulus-oocyte complexes were 
randomly selected and a biopsy of the cumulus cells was performed. Cumulus cells from two 
oocytes were sampled together and stored at -80°C for further processing. For the remaining 14 
cumulus-oocyte complexes, biopsies of cumulus cells were performed after in vitro maturation 
and 7 samples (two biopsies per sample) were stored at -80°C. 
Synchronization protocol two was used 40 days later in 40 cows, and 12 in vivo matured 
oocytes were recovered yielding 0.3 cumulus-oocyte complexes per cow.  Seven oocytes with 
evidence of cumulus cell expansion were selected and a biopsy of the cumulus cells was 
performed. 7 samples (1 biopsy per sample) were stored at -80°C. 
The analysis of variance for the three treatments (immature, in vitro matured, and in vivo 
matured) when transcriptome of denuded oocytes was analyzed showed that there was no 





Figure 3.4 Relative expression of histone methyltransferase transcripts in oocytes. 
 (p = 0.285, p = 0.093, p = 0.5, and p = 0.086, respectively). The powers of the tests performed 
were 0.095, 0.304, 0.049, and 0.319 respectively. 
It is important to mention that, even though no statistical significant differences were 
found in this experiment, two of the genes analyzed, EHMT2 (p = 0.093) and KDM6B (p = 
0.086), had p values that were not significant at the 0.05 level, but would have been significant 
at the 0.1 level. Also, the power of the ANOVA tests performed is significantly low, which is due 























































































































oocytes via TUGA is particularly challenging in the cow and limits the number of samples 
included in the experiments.   
The relative abundance of transcripts for the ASH1L, SUV39H1, KDM6B and EHMT2 for 
each sample in each treatment in Experiment three can be found in tables 3.20, 3.22, 3.24 and 
3.26, respectively.  The tables detailing the ANOVA analysis comparing the immature, in vitro 
matured, and in vivo matured treatments for the ASH1L, SUV39H1, KDM6B and EHMT2 genes 
in Experiment three can be found in the tables 3.21, 3.23, 3.25 and 3.27, respectively. 
Histograms comparing the relative abundance of transcript for ASH1L, SUV39H1, KDM6B and 
EHMT2 genes can be found in figure 3.5. 




In vitro matured  
cumulus cells 
In vivo matured  
cumulus cells  
Calibrator 1.000 1.000 1.000 
Sample 1 0.004 0.005 0.007 
Sample 2 0.001 0.052 0.003 
Sample 3 0.005 0.007 0.004 
Sample 4 0.002 0.008 0.008 
Sample 5 0.004 0.006 0.002 
Sample 6 0.007 0.448 0.001 
Sample 7 0.005 0.007 0.002 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.21 ANOVA analysis for the ASH1L gene in Experiment three 
Treatment n Missing Mean Std Dev SEM 
Immature cumulus cells 7 0 0.004 0.002 0.001 
In vitro matured cumulus cells 7 0 0.076 0.165 0.062 
In vivo matured cumulus cells 7 0 0.004 0.002 0.001 
Source of Variation DF SS MS F P 
Between groups 2 0.024 0.012 1.348 0.285 
Residual 45 0.163 0.009   
Total 47 0.187    
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In vitro matured  
cumulus cells 
In vivo matured  
cumulus cells  
Sample 1 0.013 0.040 0.015 
Sample 2 0.013 0.009 0.010 
Sample 3 0.014 0.018 0.016 
Sample 4 0.014 0.024 0.009 
Sample 5 0.018 0.018 0.007 
Sample 6 0.010 0.141 0.001 
Sample 7 0.028 0.041 0.014 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.23 ANOVA analysis for the EHMT2 gene in Experiment three 
Treatment n Missing Mean Std Dev SEM 
Immature cumulus cells 7 0 0.016 0.006 0.002 
In vitro matured cumulus cells 7 0 0.041 0.046 0.017 
In vivo matured cumulus cells 7 0 0.010 0.005 0.002 
Source of Variation DF SS MS F P 
Between groups 2 0.004 0.002 2.722 0.093 
Residual 45 0.013 0.001   
Total 47 0.017    
 




In vitro matured  
cumulus Cells 
In vivo matured  
cumulus cells  
Calibrator 1.000 1.000 1.000 
Sample 1 0.015 0.003 0.006 
Sample 2 0.010 0.010 0.002 
Sample 3 0.007 0.019 0.010 
Sample 4 0.011 0.008 0.005 
Sample 5 0.013 0.026 0.006 
Sample 6 0.229 0.269 0.001 
Sample 7 0.017 0.013 0.013 




Table 3.25 ANOVA analysis for the SUV39H1 gene in Experiment three 
Treatment n Missing Mean Std Dev SEM 
Immature cumulus cells 7 0 0.043 0.082 0.031 
In vitro matured cumulus cells 7 0 0.050 0.097 0.037 
In vivo matured cumulus cells 7 0 0.006 0.004 0.002 
Source of Variation DF SS MS F P 
Between groups 2 0.008 0.004 0.720 0.500 
Residual 45 0.097 0.005   
Total 47 0.104    
 




In vitro matured  
cumulus cells 
In vivo matured  
cumulus cells  
Sample 1 0.006 0.013 0.003 
Sample 2 0.001 0.005 0.005 
Sample 3 0.006 0.007 0.001 
Sample 4 0.002 0.013 0.001 
Sample 5 0.003 0.011 0.003 
Sample 6 0.005 0.070 0.001 
Sample 7 0.002 0.005 0.000 
Relative expression calculated as 2-ΔΔCT with Calibrator =1.   
 
Table 3.27 ANOVA analysis for the KDM6B gene in Experiment three 
Treatment n Missing Mean Std Dev SEM 
Immature cumulus cells 7 0 0.003 0.002 0.001 
In vitro matured cumulus cells 7 0 0.018 0.023 0.009 
In vivo matured cumulus cells 7 0 0.002 0.002 0.001 
      
Source of Variation DF SS MS F P 
Between groups 2 0.001 0.001 2.815 0.086 
Residual 45 0.003 0.000183   





Figure 3.5 Relative expression of histone methyltransferase transcripts in cumulus cells.  
 
3.4. Discussion 
The objective of the experiments described in this chapter was to use the difference in 
developmental competence between in vivo matured oocytes and in vitro matured oocytes to 
study the level of relative abundance of transcripts for selected histone methyltransferase 
enzymes in cumulus-oocyte complexes, oocytes and cumulus cells. Transcriptome analyses are 
particularly useful in the characterization of the in vitro vs. in vivo model because there seems 

























































































































embryo production systems. But the differences between them become evident in the 
developmental potential of the oocytes.  
The developmental potential of in vivo matured oocytes has long been known to be 
superior to the developmental potential of in vitro matured oocytes (Leibfried-Rutledge et al., 
1987). When comparing oocytes matured in vivo versus oocytes matured in vitro, even with the 
constant improvement in technology, culture systems cannot provide the same environment as 
does the maternal reproductive system. This situation has been extensively documents in cattle 
(Labrecque and Sirard, 2014). Experimental results show in vivo matured oocytes as having 
significantly higher blastocyst rates (57.65%) compared with in vitro matured oocytes (40%) 
(Humblot et al., 2005). The epigenetic landscape in bovine embryos has been correlated with 
their developmental potential (Santos et al., 2003), and delayed and incomplete reprograming in 
bovine oocytes has been reported in bovine embryos produced in vitro via nuclear transfer 
(Bourc'his et al., 2001). 
Results of the experiments showed that there is no difference in the relative abundance 
of transcripts coding for histone methyltransferases ASH1L, KDM6B and SUV39H1 in cumulus-
oocyte complexes. There was a difference in the accumulation of transcripts for histone 
methyltransferase EHMT2 between cumulus-oocytes complexes from different maturation 
systems. Transcript levels in the in vitro matured treatment were greater than the immature 
treatment and the in vivo matured treatment. No difference was found between the immature 
and the in vivo matured treatments when cumulus-oocyte complexes were evaluated.  
When oocytes were removed from their cumulus cells before transcriptome analysis the 
results changed. No differences were found for transcripts of the EHMT2, SUV39H1 and 
KDM6B genes. Significant differences were found for transcripts of the gene ASH1L. Pair-wise 
comparisons among the treatments again showed higher levels of transcripts in the in vitro 
treatment compared to the immature and in vivo matured treatments.  No difference was 
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detected between the immature and the in vivo matured treatments when denuded oocyte were 
studied.  
The analysis of the cumulus cells showed no differences in the accumulation of 
transcripts for any of the four genes of interest (ASH1L, EHMT2, SUV39H1 and KDM6B) among 
treatments when the criteria for rejection was set at the 0.05 level. However, higher 
accumulations of transcripts in the in vitro treatment for the genes EHMT2 and KDM6B could 
have been found if the criteria were changed to the 0.1 level.  Furthermore, analysis of the 
histograms suggest possible differences between treatments in transcripts of the SUV39H1 and 
KDM6B genes in oocytes and KDM6B in cumulus cells that did not show up during the 
statistical analysis. This failure to detect differences between treatments is most likely due to the 
lack of power resulting from the limited sample size.  
The first conclusion obtained from these results is that there are no differences between 
the immature and the in vivo matured treatments. Results of experiments one, two and three 
showed that there are no differences in the relative abundance of transcripts for any of the four 
histone methyltransferases included in this study (ASH1L, EHMT2, SUV39H1 and KDM6B) 
between immature cumulus-oocyte complexes, oocytes or cumulus cells and their in vivo 
matured counterparts.  
It is known that the transcription of mRNA coding for histone methyltransferases must 
occur during oocyte maturation, since epigenetic marks such as the tri-methylation of lysine 9 in 
histone 3 are not present in oocytes from primordial follicles (Fair et al., 1997) and no transcript 
accumulation for SUV39H1 was found in either primordial or primary follicles in cattle.  Follicles 
start to accumulate transcripts for this gene at the small secondary follicle stage (40-60 µm) and 
the level of transcript accumulation remained constant until the large secondary follicle stage 
(65-85 µm). It was not until the antral follicle stage that accumulation of transcripts was 
significantly higher than in more immature stages(Bessa et al., 2013). Transcript levels for 
histone methyltransferases and histone methylation levels have been reported to remain at 
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constant levels in secondary follicles, mature oocytes, and early embryos in murine, mice and 
humans (Sarmento et al., 2004; Kageyama et al., 2007; Qiao et al., 2010).  
Immature oocytes are collected from antral follicles sized 3 mm or larger. Results from 
these experiments support the idea that, by this point in the development of the oocyte, the 
levels of transcripts coding for histone methyltransferases has already reached the level that will 
be maintained until ovulation. This observation coincides with reports made for Oliveri et al. in 
2003 describing that no differences in the accumulation of transcripts were found in the levels of 
mRNA of SUV39H1, using both micro-array and QPCR technologies, between germinal vesicle 
and metaphase II oocytes in mice. 
Results from the present experiments, however, contradict another report suggesting 
that the accumulation of transcripts of EHMT2 and SUV39H1 in mice oocytes was evident 
during oocyte maturation. Immature oocytes showed basal levels of transcripts for both 
transcripts, whereas matured oocytes had between 3.5 and 5 times more transcripts for 
SUV39H1 and between 4.5 and 10 times more transcripts for EHMT2 (Kageyama et al., 2007). 
Unfortunately, the model used for most experiments comparing difference in 
transcriptome between immature and in vivo matured oocytes use mice as the model, making it 
difficult  to extrapolate and compare results. Differences among species have been postulated, 
although no experiment has yet compared differences in oocyte transcriptome among species. 
Nevertheless, histone proteins and the mechanism that regulate them are among the most 
conserved traits throughout evolution. 
Species is not the only element makes the results from transcriptome analysis during 
oocyte maturation difficult to interpret.  The experimental designs, the housekeeping genes of 
reference selected, and the starting material are major sources of variation between 
experiments.  
The selection of the reference housekeeping genes has profound repercussions in 
transcriptome analysis. Due to the variable efficiency of the RNA extraction and PCR 
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amplification techniques, the values of the real time PCR performed on the samples for the 
genes of interest must to be normalized using the value of the real time PCR performed on the 
samples for the housekeeping genes. This approach assumes that the abundance of transcripts 
of the selected housekeeping genes remains constant during the oocyte maturation process. 
Different studies have utilized different housekeeping genes, but there is a lack of information in 
regard to the transcriptional profile of the genes used frequently as reference genes in 
transcriptome analysis during maturation of mammalian oocytes.  
Also, the use of both oocytes and cumulus-oocyte complexes during transcriptome 
analysis generates differences among experiments. Bessa et al. in 2013 attributed the 
difference in the results to the methodologies followed, and elaborated that in their experiments 
oocyte measurements are more precise because they dissected the oocytes, whereas other 
experiments did not discriminate about the presence of cumulus cells. 
The reason why cumulus cells were not taken into account in most experimental 
designs, I propose, was the assumption that the oocyte was solely responsible for transcriptome 
variations, making the transcriptome of the cumulus cells irrelevant.  However, there is evidence 
now supporting the hypothesis of mRNA transfer from the cumulus cells into the bovine oocyte. 
Trans-zonal projections of the cumulus cells protrude into the zona pellucida and reach the 
oocyte membrane, and RNA-containing particles have been found in these projections. The 
projections in the bovine cumulus-oocyte complex develop at the same time as the oocyte 
undergoes cytoplasmic maturation, and the size of the projections (2 µm) would likely allow the 
transfer of larger molecules such as mRNA. Moreover, there is evidence that newly transcribed 
mRNA is sent into the projections, supporting the idea that there is an efflux of specific mRNAs 
from the cumulus cells into the transcriptionally-inactive bovine oocyte around the time of the 
germinal vesicle breakdown (Macaulay et al., 2014).  
These experiments may also provide the most reliable answer to the question about the 
accumulation of transcripts in the oocyte during the maturation period in bovine oocytes. They 
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showed that transcripts were accumulated during oocyte maturation, but only when the cumulus 
cells were present, suggesting that the cumulus cells act as an exogenous source of transcripts 
for the oocyte (Macaulay et al., 2014). This supports the approach taken during the experiments 
described in this chapter, analyzing oocytes, cumulus cells and cumulus-oocyte complexes 
separately.  
The most important findings during these experiments are the differences in transcript 
accumulation between in vitro and the other two treatments. In vitro matured cumulus-oocyte 
complexes had higher levels of transcripts coding for EHMT2 compared with the immature and 
in vivo matured treatments, and in vitro matured oocytes had higher levels of transcripts coding 
for ASH1L compared with the immature and in vivo matured treatments. Additionally, the in vitro 
matured cumulus cells had higher levels of transcripts coding for EHMT2 and KDM6B compared 
with the immature and in vivo matured treatments that were not significant at the p=0.05 level, 
but would had been significant at the p = 0.1 level ( p= 0.093 and p = 0.086, respectively). 
The results of the experiments described in this document contradict the results from 
other studies that suggest that there is a decrease in the levels of methyltransferases during in 
vitro oocyte maturation.   However, the differences in the experimental designs make a plain 
comparison of the results difficult.  
It has been reported that there was no difference in the levels of relative abundance of 
transcripts for EHMT2 across different stages of bovine oocyte maturation in cattle (Racedo et 
al., 2009), but there was a decrease in the transcript abundance of SUV39H1 at the metaphase 
II stage. This results contradict the increase in transcripts of the EHMT2 gene found in cumulus-
oocyte complexes and cumulus cells (p=0.021 and 0.093 respectively) and no difference in the 
levels of SUV39H1 transcripts (p=0.882). However the mentioned experiment reports that the 
relative abundance of transcripts for EHMT2 and SUV39H1 was significantly higher in bovine 
oocytes isolated from larger follicles (2-8 mm in size) compared with oocytes from smaller 
follicles (<2 mm in size) when the average relative abundance at four stages of development 
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(germinal vesicle, germinal vesicle breakdown, metaphase I, and metaphase II) were analyzed 
together, and concludes that in cattle the relative abundance of HMTs EHMT2 and SUV39H1 is 
affected by follicular size, with bigger follicles accumulating a larger number of transcripts 
(Racedo et al., 2009). Oocytes recovered from follicles smaller than 2 mm are highly immature, 
and perform poorly when cultured and fertilized in vitro. Comparing them against more 
competent oocytes (collected from larger follicles) might not be commensurable.  
Another study reporting a decrease in the levels of relative abundance of transcripts for 
the EHMT2 and SUV39H1 during oocyte maturation used the comparison between immature 
oocytes, in vitro matured oocytes, parthenogenetically activated oocytes and embryos produced 
via somatic-cell nuclear transfer as the experimental model (Nowak-Imialek et al., 2008) and the 
focus was on the methylation level induced in the embryo by the type of somatic cell used 
during the cloning process.  
Results from the present set of experiments suggest a loss of the regulatory 
mechanisms of transcription of histone methyltransferases when cumulus-oocyte complexes are 
cultured in vitro. There is a general up regulation of transcripts coding for histone 
methyltransferases in the in vitro culture COCs. The miss-regulation of transcripts associated 
with the developmental potential of in vitro cultured embryos has been reported previously 
(Niemann and Wrenzycki, 2000). In this case, the major changes in gene expression were 
attributed to the use of bovine serum in the maturation and culture medium. No bovine serum 
was used in the fertilization and culture media of the present experiment, but fetal bovine serum 
was used in the maturation medium.  
A direct association between changes in the expression of genes regulating epigenetic 
modifications, such as DNA methylation and histone modifications, and developmental potential 
of bovine embryos has been made (Wrenzycki et al., 2005). There has also been changes 
reported in the accumulation of transcripts which are important in the developmental potential of 
embryos produced via somatic cell nuclear transfer (Sawai et al., 2005). These reports support 
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the results of the present set of experiments, postulating that there are changes in the 
accumulation of transcripts for histone methyltransferases induced during the in vitro culture of 
the oocytes. 
Transcriptome analysis provide further insight of the oocyte maturation precess, but their 
interpretation is limited because suboptimal quality oocytes, incontrollable variables in the in 
vitro culture system, and the lack of support from proteomic analysis make it difficult to 
associate the changes in mRNA levels with the change in the phenotype observed (Labrecque 
and Sirard, 2014). Therefore, the biological interpretation of the analysis of transcriptome in this 
chapter will be evaluated in conjunction with the results of Experiments four and five, where the 




RELATIVE ABUNDANCE OF HISTONE 3 LYSINE 9 TRI-METHYLATED 
IN EARLY BOVINE EMBYOS PRODUCED IN VITRO USING IN VIVO 
AND IN VITRO MATURED OOCYTES 
 
4.1 Introduction 
 By the time of ovulation, the mammalian oocyte must have acquired the elements that 
will provide it with the developmental potential to undergo fertilization, begin cleaving, develop 
into an embryo capable of inducing a pregnancy in the mother and deliver a healthy offspring. In 
the in vitro embryo production system, ovulation is replaced by the moving of in vitro matured 
oocytes from the maturation dish into the fertilization dish, but the expectations about the 
developmental potential of in vitro matured oocytes remain the same as for their in vivo matured 
counterparts.   
 Regardless of the intense efforts to develop in vitro production systems that accurately 
mimic the in vivo conditions for embryo development, the developmental competence of in vitro 
produced embryos remains significantly lower than the developmental potential of in vivo 
produced embryos. Multiple factors have been reported as responsible, at least partially, of the 
decreased developmental potential of in vitro produced embryos. The accumulation of 
transcripts in the maturing oocyte is one of factors with the potential to compromise the 
developmental potential of the oocyte. 
In the previous chapter, evidence suggesting a miss-regulation in the accumulation of 
transcripts coding for proteins that regulate chromatin structure in in vitro matured oocytes was 
presented. In this chapter, the effect of this miss-regulation was evaluated. The levels of tri-
methylation of lysine 9 in histone 3 incorporated to chromatin was measured using 
immunocytochemistry. Comparisons between in vitro matured oocytes and in vivo matured 
oocytes were made, as well as comparisons between embryos produced in vitro from both in 
vivo matured oocytes and in vitro matured oocytes.  
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4.2 Materials and Methods 
4.2.1. Animal husbandry  
 Experimental procedures in this study were approved by the Louisiana State University 
Animal Care and Use Committee in the protocol number A2012-16 signed on July 23rd 2012 and 
were conducted at the Louisiana State University Agricultural Center Reproductive Biology 
Laboratory (RBC) - Embryo Biotechnology Laboratory (EBL) (Saint Gabriel, Louisiana) from 
August 2012 through July 2013.  
Non lacting crossbred (Angus x Red Angus x Brangus) cows (n=40) aged 4 to 7 years, 
maintained as the experimental physiology herd at the LSU RBC, were used throughout the 
course of this study. The cows displayed regular estrous cycles, were all in moderate to good 
body condition, and were maintained on pastures planted with Bermudagrass, Rye grass and 
supplemented with hay during the winter time.   
4.2.2. Experimental design  
 Two experiments were conducted to investigate the relative abundance of tri-methylated 
lysine 9 in histone 3 in matured oocytes and early embryos.  
 Experiment four: Immunocytochemistry was used to study the differences in the levels of 
the tri-methylated state of lysine 9 in histone 3 between in vitro matured oocytes and in vivo 
matured oocytes.  Experiment five: Immunocytochemistry was used to study the differences 
in the levels of the tri-methylated state of lysine 9 in histone 3 between pre-genomic activation 
embryos fertilized in vitro after in vivo or in vitro maturation.  
The experimental unit in both experiments was defined as the oocyte; the sampling unit 
in Experiment four was defined as the oocyte, whereas the experimental unit in Experiment five 
was defined as the blastomere. 
4.2.3 Synchronization for collection of cumulus-oocyte complexes 
 Two synchronization protocols were used for these experiments. The first was used to 
collect immature oocytes (germinal vesicle stage) and the second was used to collect in vivo 
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matured oocytes (metaphase II stage). These synchronization protocols are based on those 
described by Rizos (Rizos et al., 2002) and used by others to collect both in vitro matured and in 
vivo matured cumulus-oocyte complexes for transcriptome analysis (Tesfaye et al., 2009; Assidi 
et al., 2013; Spencer et al., 2013).   
 Synchronization protocol one was used to retrieve immature oocytes for use in 
experimental treatments one and two. An outline of this protocol is presented in Figure 3.1. A 
controlled internal release device with progesterone (Easi-BreedTM CIDR cattle insert®, Zoetis 
laboratories) was placed intravaginally for ten days and prostaglandin F2α (PGF2α, 25 mg of 
dinoprost tromethamine, Lutalyse®, single dose, intramuscular) was given the day of CIDR 
removal. Cows were observed for signs of estrous behavior 48 to 72 hours after the 
administration of PGF2α, and cows displaying standing estrus were identified and recorded. 
Cows that failed to display estrus during the observation period were also identified, but they 
were not removed from the experimental group. Eight days after starting estrus, growth of all 
dominant follicles was impaired using an ultrasound-guided needle. Then, four days after 
dominant follicle removal (DFR), transvaginal ultrasound-guided aspiration of follicles was 
performed.  
Synchronization protocol two was similar to protocol one; an outline of the protocol is presented 
in Figure 3.2. A CIDR in combination with PGF2α was used to synchronize estrus.  Dominant 
follicle removal was performed eight days after standing estrus and PGF2α was given four days 
after DFR. Cows displaying estrous behavior were given PGF2α and Gonadotropin releasing 
hormone (GnRH, 100 µg of Gonadorelin hydrochloride, Factrel®, single dose) intramuscular 48 
hours later. Transvaginal ultrasound-guided aspiration of oocytes was performed 12 hours after 
the administration of GnRH.  
Protocol one was used in ten cows, whereas protocol two was used in 40 animals. There was 





Figure 4.1.  Synchronization protocol for transvaginal ultrasound-guided aspiration of immature oocytes.  CIDR is controlled 
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Figure 4.2.  Synchronization protocol for transvaginal ultrasound-guided aspiration of in vivo matured oocytes.  CIDR is 
controlled internal drug release device; PGF2α is Prostaglandin F 2 alpha; DFR is dominant follicle removal; GnRH is 
Gonadotropin Releasing Hormone, TUGA is transvaginal ultrasound-guided aspiration. PM indicates that treatments were 


















Cows used in protocol one were selected randomly from the physiology herd, and all 40 cows 
from the physiology herd were used for protocol two.  
4.2.4. Collection of cumulus-oocyte complexes  
 Oocytes were collected by transvaginal ultrasound guided aspiration (TUGA) of antral 
follicles. Equipment and materials used for TUGA are presented in Appendix C. Cows were 
briefly restrained in a holding chute and given an epidural injection of 6 mL of lidocaine 2% 
(lidocaine hydrochloride, VETone® pharmaceuticals). A 7.5 MHz ultrasound transducer was 
used trans-vaginally as the ovaries were manipulated trans-rectally.  The image provided by the 
ultrasound was used by the technician to identify the follicles and direct an 18g X 8.89 cm 
needle to aspirate the follicular contents. The needle was connected by tubing to a bovine 
embryo filter with a 75 micron membrane (EmComTM Filter). A vacuum pump was connected to 
the filter to apply negative pressure, enhancing the recovery of follicular contents. 
Oocyte collection medium (OCM) was used to lubricate the surfaces with the potential to 
be in contact with the follicular contents and provide an isotonic, isothermal environment for the 
oocytes within the collection system. OCM used was Dulbecco’s phosphate-buffered saline 10X 
(DPBS, Sigma, D1283) diluted to a working concentration supplemented with 1% calf serum 
and 10 IU/ mL of heparin (Heparin sodium, Sagent® pharmaceuticals). Information about OCM 
can be found in Appendix B. Following collection, cumulus-oocyte complexes were transferred 
to a gridded dish and stereoscopic microscopes were used to search, rinse and collect COCs. 
4.2.5. In vitro maturation of cumulus-oocyte complexes 
 Treatment two of all three experiments required in vitro maturation of the cumulus-
oocyte complexes. The protocol for in vitro oocyte maturation can be found in Appendix A, the 
formulation for the maturation medium can be found in Appendix B, and a list of the equipment 
and materials used during in vitro maturation are presented in Appendix C. Immediately after 
collection and evaluation, cumulus-oocyte complexes assigned to treatment two were washed 
four times through standard maturation media and transferred into 35 µL drops of maturation 
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medium covered with 570 µL of mineral oil and incubated in 5% CO2 at 39˚ C for 22 hours. 
Maturation medium was tissue culture medium 199 supplemented with fetal bovine serum, 
sodium pyruvate, glutamine, FSH and a mix of penicillin and streptomycin. 
4.2.6. In vitro fertilization of cumulus-oocyte complexes 
 After oocytes were matured, in vitro fertilization was performed as per the protocol in 
Appendix A. Refer to Appendix B for media formulations.  Oocytes were moved in groups of 
approximately ten to 48 µL IVF-TALP drops covered with 570 µL of mineral oil in four-well 
plates, which had been equilibrated in 5% CO2 at 39°C for at least two hours prior to the addition 
of the oocytes.  Two straws of bull semen were thawed at 37°C for 30 seconds in a water bath 
and added on top of an ISolate® (99264, Irvine Scientific®) density gradient.  The gradient was 
centrifuged at 400g for 20 minutes, washed with 5 mL of IVF-TALP and centrifuged for 10 
minutes, then washed with 2 mL of IVF-TALP and centrifuged for 5 minutes.  The number of 
sperm in the pellet was counted using a hemocytometer and a fertilization suspension of IVF-
TALP and sperm was prepared at a 1x106 sperm/mL concentration. A 2 µL volume of this 
sperm suspension was added to each 48 µL drop of IVF-TALP with oocytes, and the dishes 
were placed back into the 5% CO2 incubator at 39°C. 
4.2.7. In vitro culture of embryos  
 At 18 hours post-fertilization, the presumptive zygotes were removed from IVF drops, 
placed into a warmed hyaluronidase solution and vortexed at max speed for 4 to 7 minutes until 
all cumulus cells were removed.  They were then washed through a pre-warmed, pre-
equilibrated SOFaa culture medium and placed into 35 µL drops of culture medium under 570 
µL of mineral oil in four-well plates. Embryos were then cultured for 60 hours in 5% CO2 at 
39°C.  Refer to Appendix B for media formulations.  
4.2.8 Immunocytochemistry 
  Mature oocytes were fixed by placing the samples into a paraformaldehyde solution 
(15710, Electron Microscopy Sciences ) and then moved into a 88% methanol solution (M1775-
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1GA, Sigma-Aldrich™). Membranes ware permeated with a PBST solution containing Tween 20 
(161-0781, BIO-RAD®). Unspecific binding was prevented by blocking the samples in a 
commercial blocking solution (Maxblock Blocking Medium®, 15252, Active Motif™) overnight at 
4°C. After washing the samples with Maxwash™ Washing Medium (15254, Active Motif®) for 10 
minutes on top of a shaking plate, oocytes were incubated for one hour at 37˚C within a 
polyclonal antibody to histone 3 tri-methylated lysine 9 (GR164977-1, Abcam®) produced in 
rabbits. Samples were washed 3 times with Maxwash™ Washing Medium (15254, Active 
Motif®) for 10 minutes on top of a shaking plate before being incubated for one hour at 37°C 
within a goat anti-rabbit IgG labeled Chromeo™ 488 (15041, Active Motif®) diluted in Maxbind™ 
Staining Medium (15253, Active Motif®). Samples were washed 4 times with Maxwash™ 
Washing Medium (15254, Active Motif®) for 10 minutes on top of a shaking plate before being 
mounted in microscopy slides using ProLong® gold antifade reagent (P36930, Molecular 
proves® by life technologies™). 
4.2.9. Deconvolution microscopy  
 A Leica DM RXA2 upright microscope with DAPI (ex 340-380/em450-490) and 
FITC/GFP (ex 460-500/em512-542) filter sets was used to capture the microscope images.  The 
exposure time and the Z-stack distance were maintained constant within and between 
treatments. Fluorescent intensity from regions of interest (FIRI) was measured using SlideBook 
5.5® digital microscopy software (3i ™). Regions of interest were defined as an area of the 
image that completely contained one and only one structure of interest (metaphase plate of the 
oocyte in Experiment 4 and the nucleus of each blastomere in Experiment 5) from which 
fluorescent intensity could be calculated. These regions of interest had constant area within 
treatments and between treatments in each experiment. Fluorescent intensity from the 
background (FIB) was measured in an area equal to the regions of interest and from a section 
of the image representative of the intensity of the background. The value of fluorescent intensity 
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of the sample (FIS) was defined as FIS = FIRI – FIB (Fluorescent intensity of the sample = 
Fluorescent intensity of the regions of interest - Fluorescent intensity of the background). 
4.2.10. Confocal microscopy  
 A Zeiss SteREO Lumar V.12® upright microscope with DAPI (ex 359-371/LP397) and 
FITC/GFP (ex 450-490/em500-550) filter sets was used to capture the microscope images.  The 
exposure time and the Z-stack distance were maintained constant within and between 
treatments. Fluorescent intensity from regions of interest (FIRI) was measured using SlideBook 
5.5® digital microscopy software (3i™). Regions of interest were defined as an area of the 
image that completely contained one and only one structure of interest (metaphase plate of the 
oocyte in Experiment 4 and the nucleus of each blastomere in Experiment 5) from which 
fluorescent intensity could be calculated. These regions of interest had constant area within 
treatments and between treatments in each experiment. Fluorescent intensity from the 
background (FIB) was measured in an area equal to the regions of interest and from a section 
of the image representative of the intensity of the background. The value of fluorescent intensity 
of the sample (FIS) was defined as FIS = FIRI – FIB (Fluorescent intensity of the sample = 
Fluorescent intensity of the regions of interest - Fluorescent intensity of the background). 
4.2.11. Statistical Analysis 
Fluorescence analysis was performed using SlideBook® 5.5 (3i intelligent imaging 
innovations™) digital microscopy imaging software. A picture of the analysis of fluorescence 
intensity can is shown in Figure 4.3. Fluorescence data was exported in Microsoft Excel 2010 
spreadsheet format.  Differences in fluorescence levels between treatments were analyzed 
using Student’s t-test using SigmaStat® Statistical Software (version 3.5). Differences of P < 
0.05 were considered to be significant.  
4.3. Results  
In experiment four, ten cows were synchronized following protocol 1 and 54 cumulus- 




Figure 4.3 Analysis of fluorescent intensity during Experiment four. Fluorescent intensity is measured using Slidebook 5.5® software. 
The sample is an in vitro matured oocytes shortly before reaching the metaphase II stage. Intensities from two areas of interest 
where the fluorescent tri-methylated lysine 9 in histone 3 signals are detected are captured and exported to Excel® Microsoft Office™ 
software for further analysis. A third region of interest capturing the intensity of the background is also taken to be used to normalize 
the data.  
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complexes collected per cow. Cumulus-oocyte complexes were matured in vitro for 22 hours. 40 
cows were synchronized using protocol two and 15 in vivo matured oocytes were recovered, 
yielding an average of 0.0375 oocytes per cow. Morphological evaluation was used to select 24 
cumulus-oocyte complexes from the in vitro matured group and 6 cumulus-oocyte complexes 
from the in vivo matured group. Morphological evaluation was based on homogeneity of the 
ooplasm and clear evidence of cumulus expansion. 
 Cumulus cells were removed before fixing and staining the oocytes. A primary antibody 
developed in rabbits against tri-methylated lysine 9 in histone 3 was complemented with a 
secondary goat-anti rabbit antibody labeled with a fluorescent prove. Samples in both 
treatments were stained simultaneously using the same batch of staining solutions to minimize 
difference due to sample processing. 
Fluorescence intensity was captured using a deconvolution microscope and analyzed using 
microscopy imaging software. The results are presented in Table 4.1 There were lower levels of 
tri-methylation of lysine 9 in histone 3 in in vitro matured oocytes  compared with in vivo matured 
oocytes (p < 0.001).   
Table 4.1 Student’s t test of in vitro matured oocytes versus in vivo matured oocytes 
t = -3.867 with 26 degrees of freedom (p < 0.001).  Power of the test with alpha = 0.05: 0.964 
In experiment five, ten cows were synchronized following protocol 1 and 62 cumulus-
oocyte complexes were recovered, yielding an average of 6.4 immature cumulus-oocyte 
complexes collected per cow. Cumulus-oocyte complexes were matured in vitro for 22 hours. 40 
cows synchronized using protocol two were aspirated and 17 in vivo matured oocytes were 
recovered, yielding an average of 0.425 oocytes per cow. Morphological selection was used to 
Treatment n Missing Mean Std Dev SEM 
In vitro matured oocytes 6 0 468941.67 485620.92 198253.91 
In vivo matured oocytes 24 0 5109783.17 2892383.11 590405.23 
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select 35 cumulus-oocyte complexes from the in vitro matured group and ten cumulus-oocyte 
complexes from the in vivo matured group. Fluorescence intensity was captured using a 
deconvolution microscope and analyzed using microscopy imaging software. The results are 
presented in Table 4.2. 
Table 4.2 Student’s t test of embryos derived from in vitro matured oocytes versus embryos 
derived from in vivo matured oocytes 
Treatment n Missing Mean Std Dev SEM 
Blastomeres from embryos 
from in vitro matured oocytes 
89 0 136375.63 75967.22 8052.51 
Blastomeres from embryos 
from in vivo matured oocytes 
24 0 204348.54 122960.08 25099.12 
t = -3.366 with 111 degrees of freedom (p < 0.001).  Power of the test with alpha = 0.05: 0.909. 
Morphological selection was based on clear evidence of cumulus expansion. Oocytes 
from both treatments were fertilized in vitro simultaneously but separately. Embryos from both 
treatments were cultured in vitro for 60 hours simultaneously, under the same culture condition, 
in separate dishes. Six embryos (60%) cleaved from the ten in vivo matured oocytes fertilized in 
vitro: one embryo developed to the two-cell stage (16%), two embryos developed to the three-
cell stage (33.3%), two embryos developed to the four-cell stage (33.3%), and one embryo 
developed to the eight-cell stage (16%). 22 embryos (62.85%) developed from the 35 in vitro 
matured oocytes fertilized in vitro: two embryos developed to the two-cell stage (9.09%), three 
embryos developed to the three-cell stage (13.6%), 13 embryos developed to the four-cell stage 
(54.16%), two embryos developed to the five-cell stage (9.09%), one embryo developed to the 
six-cell stage (4.54%), and one embryo developed to the eight-cell stage (4.54%). 
After culture, a primary antibody developed in rabbits against tri-methylated histone 3 
lysine 9 was complemented with a secondary goat-anti rabbit antibody labeled with a 
fluorescent dye. Samples in both treatments were stained simultaneously using the same batch 
of staining solutions to minimize differences due to sample processing.  
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 There was a significant difference (p=<0.001) in the level of tri-methylation of lysine 9 in 
histone 3 between in the blastomeres of embryos derived from in vitro matured oocytes 
compared with embryos derived from in vivo matured oocytes.   
4.4. Discussion 
Collection of immature cumulus-oocyte complexes (COCs) yielded an average of 7.3 
COCs per cow in Experiment one, 5.9 COCs per cow in Experiments two and three, 5.4 oocytes 
per cow in Experiment four and 6.4 oocytes per cow in Experiment five. An in vivo matured 
cumulus-oocyte complex was collected from 47.5% of the cows aspirated for Experiment one, 
30% of the cows aspirated for Experiments two and three, 37.5% of the cows aspirated in 
Experiment four, and 42.5% of the cows aspirated in Experiment five. The recovery rate of 
immature COCs is close to the commercial recovery rates for cows that do not receive ovarian 
stimulation during the synchronization protocol.  Reduced recovery rates are associated with 
proximity to ovulation (Humblot et al., 2005) and represents the main reason why commercial 
biotechnology companies working with cattle collect almost exclusively immature oocytes for 
their in vitro embryo production systems.   
The use of drug-mediated ovarian stimulation was considered during the design of the 
synchronization protocols. It was evident that it would benefit the number of samples that could 
be collected, the timeframe of the experiment, and the amount of work required. However, 
evidence that the use of superstimulating drugs induce changes in gene expression in both 
cumulus cells and oocytes, specifically genes associated with oxidative stress and 
differentiation (Dias et al., 2013), was used to decide against any ovarian stimulation. 
GnRH was used in the synchronization protocol to stimulate the release of LH, which is 
responsible for the final nuclear maturation of the intrafollicular oocyte. It has been shown that 
the use of GnRH for a LH surge induction does not provide any substantial changes in regard to 
the transcriptional status of the preovulatory oocyte (Humblot et al., 2005). 
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These synchronization protocols yielded follicles for aspiration from 3 to 12 mm in 
diameter, which were all aspirated. Follicular size was not considered during the collections 
because developmental competence of the oocyte does not relate to follicular size or 
developmental competence of the follicle, and factors negatively affecting follicular development 
(such as atresia) can enhance oocyte competence (Arlotto et al., 1996). 
Morphological evaluation of immature cumulus-oocyte complexes in Experiment one 
was used to select 87.6% of the oocytes collected to be assigned either to the immature or the 
in vitro matured treatment. The percentage of immature cumulus-oocyte complexes that passed 
the morphological evaluation was 47.4% in Experiments two and three, 44% in Experiment four, 
and 56.4% in Experiment five. The large variability in the quality of the oocytes retrieved via 
transvagial ultrasound guided aspiration of follicles (TUGA) can be explained by differences in 
follicular counts between cows, variability in the response to the synchronization protocols, 
changes in management conditions of the herd and conditions during the collection session.  
The differences in follicular counts between cows in the physiology herd are substantial. 
There are some cows that average 35 COCs recovered per collection session whereas others 
average no more than 4 COCs per session (data not shown). The cows were selected randomly 
from the herd to prevent bias, resulting in high variability in the recovery rates.  
Cows respond differently to synchronization protocols, and even though most of the 
cows were in the middle of a follicular wave, some cows had dominant follicles at the time of 
TUGA, producing oocytes that were reasonably questionable within the selection criteria for the 
experiment, which was that the cumulus-oocyte complex had not had the opportunity to undergo 
maturation in vivo. Rejecting COCs suspected of in vivo maturation affected the recovery rates 
of the project. 
The changes in management that affected the recovery rates were mainly associated 
with changes in the weather and, therefore, in the nutritional status of the herd. The limited 
number of cows in the physiology herd at the RBC, the length of the synchronization protocols, 
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the rest intervals given to the cows between protocols, and other research projects conducted in 
parallel with this project resulted in collection sessions that were months apart from each other. 
Changes in the average number of follicles present in the ovaries of the cows were observed 
among the different seasons in which the cows were examined with ultrasound equipement. 
 Changes in the conditions during the oocyte collection sessions can influence the 
recovery rates and the quality of the cumulus-oocyte complexes retrieved. Changes in 
personnel, effectiveness and duration of the epidural anesthesia, cow temperament and 
behavior, room temperature and effective negative pressure of the vacuum pump determined 
the number and quality of the cumulus-oocyte complexes recovered.  
However, cows that did not display estrus after the CIDR + prostaglandin portion of the 
protocol were not removed from the experimental group because the developmental 
competence of the oocyte relates directly to the developmental status of the follicle, but no 
association has been found with the corpus luteum (Vassena et al., 2003) and developmental 
competence has been proposed to be independent of the phase of the estrus cycle where 
oocytes are collected (Arlotto et al., 1996). Therefore, even if a small group of cows failed to 
become synchronized with the majority of the herd, as long as they respond to the final 
injections of prostaglandin given and develop a dominant follicle while displaying estrous 
behavior, a competent in vivo mature oocyte should be retrieved during the follicular aspiration. 
In the in vivo matured oocyte treatment, the percentage of oocytes that passed the 
morphological evaluation was 84.2% in Experiment one, 58.3% in Experiments two and three, 
40% in Experiment four and 58.8% in Experiment five. The criteria to select an in vivo matured 
oocyte were homogeneous ooplasm and evidence of substantial expansion of the cumulus 
cells. The use of cumulus expansion as a criterion for oocyte maturation has been questioned 
because there is evidence that human oocytes occasionally expand the cumulus cells without 
reaching the metaphase II stage (Veeck, 1988). However, there is no difference in the 
fertilization rates between oocytes confirmed to be in MII and oocytes with cumulus expansion 
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with no clear meiosis status. This means that even though a small number of oocytes may have 
delayed nuclear maturation, cytoplasmic and molecular maturation have taken place before 
cumulus expansion (Veeck, 1988). 
 However, cumulus cell expansion was kept as a selection criterion for technical 
reasons. During the collection of large follicles it is recommended not to access the dominant 
follicle with the needle coming from the top directly into the few layers of granulosa cells 
surrounding the antral cavity because disruption of the follicular wall of large follicles tends to 
occur when contacted with the needle, and when this happens the oocytes are seldom 
recovered. Instead, large follicles must be approached with the needle going through the 
ovarian medulla. Unfortunately, during this approach immature cumulus-oocyte complexes can 
get in contact with the needle, resulting in the unintended collection of immature Cumulus-
oocyte complexes instead of the mature cumulus-oocyte complex targeted for collection. .  
 The percentage of oocytes that cleaved after fertilization was 60% in the in vivo matured 
treatment and 62.85% in the in vitro matured treatment. The results of IVF following TUGA of 
oocytes vary greatly. There are reports of blastocyst rates as low as 54% (Merton et al., 2003) 
and some others with 81.9% +/- 8.7% morula rates and 80.4% +/- 9.4% blastocyst rates 
(Blondin et al., 2002). In Experiment five, the percentage of embryos that cleaved in the in vitro 
matured oocyte treatment seemed high, because it is expected that embryos developing from 
oocytes matured in vitro have lower developmental competence than their in vivo matured 
counterparts. The reason for this high cleavage rate is unknown, but it might have been 
influenced by the strict morphological selection applied after collection, allowing a healthy cohort 
of oocytes to develop better than average. Also, 22.6% of the embryos in the in vitro matured 
oocyte treatment did not develop further than the three-cell stage in the 60 hours of culture. This 
percentage can be interpreted as embryos that cleaved, but lacked developmental potential to 
continue growing.  
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 Experiments four and five demonstrated a difference in the levels of tri-methylation of 
lysine 9 in histone 3 between embryos developing from in vitro matured oocytes and in vivo 
matured oocytes. These findings are consistent with the loss of regulation in the accumulation of 
transcripts for histone methyltransferases during the in vitro maturation of bovine oocytes 
described in Experiments one, two, and three. The specific characteristics of the ooplasm that 
determine the developmental competence of the oocyte are still unknown, but it is accepted that 
the embryonic programs for developmental competence are embedded during oocyte 
maturation, which is done in part by accumulation of reserves of molecules that later support 
embryonic development (Macaulay et al., 2014). 
 Results of Experiment four showed that the level of tri-methylation of lysine 9 in histone 
3 is higher in in vivo matured oocytes than in vitro matured oocytes. The influence of oocyte 
quality on the developmental potential of the embryo has been recognized in the cow more 
clearly than in any other species (Sirard et al., 2006); It has been demonstrated that 
developmental potential is higher in in vivo matured oocytes than in vitro matured oocytes, it is 
plausible that the decrease in the level of tri-methylation of lysine 9 in histone 3 is one of the 
components involved in the decrease of developmental competence detected during the in vitro 
maturation of oocytes.  
The lower levels of methylation of lysine 9 in histone 3 observed in in vitro matured 
oocytes in experiment four were also observed in the in vitro produced embryos from in vitro 
matured oocytes in experiment five. Embryos developing from in vitro matured oocytes showed 
lower levels of H3K9 tri-methylation than the embryos developing from in vivo matured oocytes 
in the present study. 
Experiments one through three showed a lack of regulation in the accumulation of 
transcripts for histone methyltransferases in oocytes matured in vitro.  One of the effects of this 
lack of regulation seems to be the decrease in the level of tri-methylation of H3K9 in the in vitro 
derived embryos. Based on the superior developmental competence of embryos produced from 
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oocytes matured in vivo compared against oocytes matured in vitro, results in the present set of 
experiments suggest that the up regulation of transcripts for histone methyltransferases causes 
a decrease in the level of histone methylation in the embryo that compromises its 
developmental potential.  
Following the rationale behind the central dogma of molecular biology, the increase in 
the level of transcripts of histone methyltransferases suggest a consequent increase in the level 
of methylation of histone 3. But this assumption contradicts the decrease in the methylation 
levels observed in Experiments four and five. Therefore, it is possible that the in vitro culture of 
bovine oocytes induces a lack of regulation in the accumulation of transcripts coding for some 
histone methyl transferases and mechanisms associated with the posttranscriptional regulation 
of transcripts.  It is possible to postulate that miRNAs target mRNAs for destruction, resulting in 
a lower expression of the phenotype.  
Methylation of histone 3 at lysine 9 is not found in the oocyte at early stages of 
development, at least in pig oocytes (Bui et al., 2007). However, it becomes a constant 
epigenetic mark during oocyte maturation (Racedo et al., 2009). It means that the levels of tri-
methylation of lysine 9 in histone 3 have to be acquired and maintained during oocyte 
maturation. Suboptimal maturation of the oocyte (induced by suboptimal in vitro maturation 
systems) has the potential to generate extensive modifications in the levels of this epigenetic 
mark.  
The methylation of lysine 9 in histone 3 has three biological functions as an epigenetic 
mark. It serves as a mark to silence genes in euchromatic regions, it regulates the formation of 
heterochromatin regions, and it serves as an epigenetic mark for genes that are the target of the 
pluripotency genes in stem cells (when used in combination with other epigenetic marks).  
In the metaphase II oocyte, since it is considered transcriptionally incompetent, the 
biological consequences of hypo-methylation of lysine 9 in histone 3 most likely will not be 
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related with gene silencing. But in the early embryo, the silencing of unnecessary genes is 
required to acquire the transcriptome needed to progress to development.  
Methylation of histone 3 at lysine 9 is an important regulator of mammalian embryonic 
development because it serves as a specific binding site for the recruitment of Heterochromatin 
protein 1, which is one of the major proteins that modify chromatin to create heterochromatic 
regions and silence genes (Nowak-Imialek et al., 2008). Chromatin configuration of the oocyte is 
symptomatic of its developmental potential. Chromatin condensation and spatial reorganization 
have to occur gradually and orderly to maximize competence (Lodde et al., 2013) . Therefore, 
lower levels of tri-methylated lysine 9 in histone three can affect developmental potential of the 
early embryo by either preventing the condensation of chromatin or by changing the timing of 
chromatin compaction and gene silencing.  
Another important possible consequence of the loss of regulation in the accumulation of 
transcripts for histone methyltransferases and the lower level of methylation of lysine 9 in 
histone 3 induced by the in vitro culture of oocyte and embryos is the interference with other 
elements of the histone code. It has been shown that the combination of epigenetic marks can 
be used by embryonic stem cells to label genes that are required during early development 
(Bernstein et al., 2006). Specifically, the presence of the double mark H3K4me3 and H3K9me3 
in the same gene suggests that some developmental important genes are pre-activated, but do 
not become active until the repressive mark is removed (Bernstein et al., 2006).  
Finally, hyper-methylation of H3K9 also has been described in embryos produced from 
somatic cell nuclear transfer (cloning), but the difference in the level of this epigenetic mark was 
associated to the origin of the somatic cell used during the nuclear transfer process (Nowak-
Imialek et al., 2008). It is not clear if the in vitro culture of cloned embryos has any affect in the 
accumulation of transcripts for histone methyltransferases or the methylation levels in the 





SUMMARY AND CONCLUSIONS 
A set of five experiments was conducted to explore the association between post-
translational modification of histones and the developmental competence of bovine oocytes and 
embryos. In the first three experiments, the well-established difference in developmental 
competence between in vivo matured oocytes and in vitro matured oocytes was used to 
investigate possible changes in the accumulation of transcripts of key histone methyltransferase 
enzymes. In experiments four and five, the changes in transcript accumulation established in 
experiments one through three was used to study the changes in the level of the accumulation 
of a specific post-translational modification in mature oocytes and early embryos.  
In experiment one, cumulus-oocyte complexes were assigned to one of three 
treatments: immature, in vitro matured, and in vivo matured. The relative abundance of 
transcripts for the histone methyltransferases ASH1L, EHMT2, SUV39H1, and KDM6B was 
calculated using the abundance of the housekeeping genes POLYA and GADPH. Results 
showed that there is no difference in transcript accumulation for the four genes of interest 
between the immature and the in vivo treatment.  This suggests that there is no major 
accumulation of transcripts for histone methyltransferases in cumulus-oocyte complexes after 
the follicle reaches the antral stage. A difference in the accumulation of transcripts for the 
EHMT2 gene was determined, and the pair-wise comparison showed that the accumulation of 
transcripts for this gene in in vitro matured oocytes is higher than in the immature and in vivo 
matured oocytes (p = 0.021 and p = 0.007, respectively).  
In Experiment two, oocytes were assigned one of three treatments: immature, in vitro 
matured, and in vivo matured. Again, the relative abundance of transcripts for the histone 
methyltransferases ASH1L, EHMT2, SUV39H1 and KDM6B was calculated following previous 
protocols. Results showed that there are no difference in transcript accumulation for the four 
genes of interest between the immature and the in vivo treatment, supporting the prior 
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conclusion that there are no major accumulations of transcripts for histone methyltransferases in 
oocytes after they reach the growth phase. A difference in the accumulation of transcripts for the 
ASH1L gene was determined, and the pair-wise comparison showed that the accumulation of 
transcripts for this gene in in vitro matured oocytes is higher than in the immature and in vivo 
matured oocytes (p = 0.001 and p = 0.001, respectively). This finding suggests that a lack of 
regulation in the transcription of genes for specific histone methyltransferases can be induced 
by the in vitro culture conditions.  
In Experiment three, cumulus cells were assigned to one of three treatments: immature, 
in vitro matured, and in vivo matured. Again, the relative abundance of transcripts for the 
histone methyltransferases ASH1L, EHMT2, SUV39H1, and KDM6B were calculated. Results 
showed no difference in transcript accumulation for the four genes of interest between the 
immature cumulus cells and the in vivo matured cumulus cells. Recent studies have 
demonstrated the transmission of transcript from the cumulus cells to the oocyte during late 
stages of oocyte maturation when the oocyte is transcriptionally incompetent. Results suggest 
that the transfer of transcripts coding for histone methyltransferases during in vivo maturation of 
bovine oocytes is very unlikely.  
No differences in the accumulation of transcripts for any of the histone 
methyltransferases in the study was found in the cumulus cells in the vitro treatment. However, 
the accumulations of transcripts for the EHMT2 and KDM6B genes would had been significant 
had the p value been set to p=0.1 instead of p=0.05. The p values for the ANOVA analysis of 
these two genes were p = 0.093 and p = 0.086, respectively.  Results in this experiment are 
inconclusive in regard to the lack of regulation of transcription for histone methyltransferase 
genes induced by the in vitro culture of embryos.  
Based on results of previous experiments suggesting a lack of regulation in the 
accumulation of transcripts coding for histone methyltransferases induced by the in vitro culture 
of cumulus-oocyte complexes, experiment four was designed to investigate changes in the 
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levels of histone methylation between in vivo matured bovine oocytes and in vitro matured 
oocytes. A polyclonal antibody against the tri-methylated lysine 9 in histone 3 (H3K9me3) was 
coupled with a secondary antibody labeled with a fluorescent dye to semi-quantify the relative 
abundance of the H3K9me3 post-translational modification. Results showed that the in vitro 
matured oocytes displayed lower levels of H3K9me3 than their in vivo matured counterparts.  
Since in vivo matured oocytes are more competent than in vitro matured oocytes and 
post-translational modifications of histones affect developmental competence, results in this 
experiment suggest that the in vitro culture of oocytes induce modifications in the accumulation 
of transcripts of the enzyme EHMT2 (which is responsible for the tri-methylation of lysine 9 in 
histone 3) resulting in lower levels of H3K9me3 that can affect the developmental competence 
of oocytes matured in vitro.  
To provide more support for this idea, in experiment five in vitro matured oocytes and in 
vivo matured oocytes were fertilized in vitro and the levels of H3K9me3 were evaluated after 60 
hours of in vitro culture. It was important to evaluate the embryos at this early stage because we 
wanted to determine the effect of the maternal transcriptome in the level of post-translational 
modification of histones, and genomic activation of the bovine embryo occurs around the 8-cell 
to 16-cell stage.  
Results of experiment five showed lower levels of H3K9me3 in the in vitro treatment 
compared against the in vivo treatment. Once again, there is evidence suggesting that the in 
vitro culture system induces a lack of regulation in the accumulation of transcripts for histone 
methyltransferases that results in lower levels of post-translational modification of histone that 
are crucial for the developmental competence of the embryo.  
It is important to elaborate on how an increase in the level of transcripts coding for a 
methyltransferase enzyme may result in a decrease in the phenotype catalyzed by the enzyme. 
It could be argued that higher level of transcripts of a histone methyltransferase should result in 
higher levels of methylation of the histone. But this argument ignores the regulatory 
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mechanisms and checkpoints that cells have to regulate transcription and translation. We 
propose that the increase in the transcription levels triggers a posttranscriptional regulatory 
mechanism within the cell that results in the existing phenotype. It is not clear which post 
transcriptional mechanisms would be involved, but it is possible to suggest that miRNA targeting 
transcripts for histone methyltransferases could result in a phenotype with lower levels of 
histone methylation in the chromatin.  
In regard to the biological interpretation of the consequences of the lower levels of 
histone methylation that have the potential to harm the developmental potential of the embryos, 
it can be hypothesized that the major effects of the lower levels of H3K9me3 would affect 
chromatin compaction, gene silencing, and epigenetic marks of genes required during early 
development. H3K9me3 has been found associated with the promoter regions of genes that are 
transcriptionally silent. Either by competing with transcription factor or by recruiting chromatin 
modifying proteins, H3K9me3 has been shown to prevent transcription of targeted genes. 
H3K9me3 also has the capability to recruit heterochromatin protein 1, which is the major protein 
factor regulating chromatin compaction and the formation of heterochromatin. Lower levels of 
H3K9me3 in embryos could affect the compaction of chromatin through the cell cycle as the 
silencing of clusters of genes.  
Lastly, H3K9me3 has been found associated with H3K4me3 in the promoter region of 
genes that are targeted by the pluripotency genes of embryonic stem cells. This epigenetic mark 
has been described as a mark for pre-activated genes; genes that are epigenetically labeled to 
be transcribed but require the removal of the repressive mark to become active. Losing 
H3K9me3 marks can potentially result in the loss of regulation of these pre-activated genes, 
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In vitro Maturation of Cumulus-Oocyte Complexes 
1. Prepare bovine maturation media and HEPES-TALP media. Media formulations can be 
found in Appendix B.  
2. Place 35 µL drops of maturation media in 4-well dishes (1 drop per well) and cover them 
with 570 µL of mineral oil. Carefully place the dishes with the media drops into a 5% CO2 
incubator set at 39˚C for at least two hours to equilibrate.  
3. Rinse the immature cumulus-oocyte complexes once through HEPES-TALP medium. 
4. Rinse the immature cumulus-oocyte complexes four times through maturation medium. 
5. Eight to twelve cumulus-oocyte complexes are placed in each maturation media drop for 
22 hours.  Oocytes are then removed from the incubator and processed for 
immunocytochemistry.  
PCR Amplification 
JumpStart™ REDTaq® ReadyMix™ reaction mix 
Catalog number P0982, Sigma-Aldrich Inc. 
1. Reactions are carried out in PCR tubes in a volume of 50 µL per reaction.  
2. 5 µL of calibrator DNA is added to 25 µL of JumpStart™ REDTaq® ReadyMix™, 2 µL of 
forward primer, 2 µL of reverse primer, and 6 µL of nuclease-free water.  
3. PCR tubes were placed in the thermocycler and run with the following protocol: 
a. 1 cycle  
i. 2 minutes at 94˚C  
b. 35 cycles 
i. 30 seconds at 94˚C (Denaturation) 
ii. 30 seconds at 61˚C (Annealing) 
iii. 1 minute at 72˚C (Extension) 
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c. 1 cycle 
i. 5 minutes at 72˚C (Final extension) 
d. Hold at 4˚C until removed from the thermocycler. 
RNA Extraction 
RNeasy® Plus Micro Kit 
Catalog number 74034, QIAGEN® 
1. Add 350 µL of buffer RLT Plus directly to the tube containing the sample while still at  
-80°C (add buffer while tube is still in the freezer). 
2.  Vortex for two minutes at maximum speed. 
3. Transfer lysate to a gDNA Eliminatorspin column placed in a 2 mL collection tube. 
Centrifuge for 30 seconds at 9,000 X g. Discard the column and save the flow-through. 
4. Transfer the sample to an RNeasy MinElute spin column placed in a 2 mL collection 
tube. Close the lid and centrifuge for 15 seconds at 9,000 X g. Discard flow-though. 
5. Add 700 µL of buffer RW1 to the RNeasy MinElut spin column. Close the lid and 
centrifuge for 15 seconds at 9,000 X g. Discard the flow-through. 
6. Add 500 µL of buffer RPE to the RNeasy MinElut spin column. Close the lid and 
centrifuge for 15 seconds at 9,000 X g. Discard the flow-through. 
7. Add 500 µL of 80% ethanol to the RNeasy MinElut spin column. Close the lid and 
centrifuge for 15 seconds at 9,000 X g. Discard the collection tube with the flow-through. 
8. Place the RNeasy MinElute spin column in a new 2 mL collection tube. Leave the lid 
open and centrifuge at max speed for 5 minutes to dry the membrane. Discard the 
collection tube with the flow-through. 
9. Place the RNeasy MinElute spin column in a new 1.5 mL collection tube. Add 17 µL of 
RNase-free water directly to the center of the spin column membrane. Close the lid 
gently and centrifuge for 1 minute at max speed. 
10. RNA will be eluted in a volume of approximately 15 µL.  
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Reverse Transcriptase PCR 
iSCRIPT cDNA Synthesis Kit 
Catalog number 170-8890, Bio-Rad Laboratories®, Inc. 
1. Reactions are carried out in PCR tubes in a volume of 20 µL per reaction.  
2. 15 µL of mRNA from each sample are added to 1 µL of reverse transcriptase enzyme 
and 4µL of iSCRIPT reaction mix. If less than 15 µL of sample is available, nuclease-free 
water can be added to the reaction to complete the final 20 µL volume per reaction.  
3. PCR tubes are placed in the thermocycler and run for a single cycle with the following 
protocol: 
a. 5 minutes at 25˚C  
b. 30 minutes at 42˚C 
c. 5 minutes at 85˚C 
d. Hold at 4˚C 
Real Time PCR 
SsoFast™ EvaGreen® Supermix  
Catalog number 172-5200, Sigma-Aldrich Inc. 
1. Reactions are carried out in 96-well PCR plates, using a volume of 20 µL per reaction.  
2. Set up plate-template map and upload the template into the computer controlling the 
thermocycler.  
3. Prepare master mixes per gene. Master mixes are prepared to minimize variations due 
to pipetting small volumes. Negative controls take nuclease-free water instead of a 
sample and positive controls use a selective dilution of the calibration preparation. Each 
sample, positive control, and negative control is run in triplicate. 
4. 12 µL of cDNA of each sample is added to 30 µL of SsoFast™ EvaGreen® Supermix, 3 
µL of forward primer, 3 µL of reverse primer, and 12 µL of nuclease-free water. The 60 
µL mix is vortexed and placed in the PCR plates as three replicates of 20 µL each.  
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5. Place the PCR plate in the thermocycler and cover it with sealing tape. Run with the 
following protocol: 
a. 1 cycle  
i. 1 minute at 95°C (Activation) 
b. 40 cycles 
i. 5 seconds at 95°C (Denaturation) 
ii. 30 seconds at 61°C (Annealing and extension) 
c. 68 cycles 
i. Increase 0.5°C every 10 seconds starting at 61°C and finishing at 95°C 
(Melting curve) 
In vitro Embryo Fertilization and Culture 
1. Move two centrifuge carriers into an incubator (39°C).  
2. Prepare IVF-TALP. Media formulation can be found in Appendix B.  
3. Make fertilization wells: 
a. 48 µL IVF-TALP drops in each well of a 4-well plate. There will be 8-12 oocytes 
per drop.  Cover with pre-warmed, pre-equilibrated mineral oil. 
b. Add 500 µL IVF-TALP in each well of a 4-well plate for use as washing dishes. 
c. Equilibrate everything in the 5% CO2 incubator for at least 2-3 hours.  
4. Place the tube with remaining IVF-TALP medium into the 5% CO2 incubator (loosened 
cap) at 39°C to equilibrate. 
5. Prepare Percoll Gradient: Fill a 15 mL centrifuge tube with 2 mL of upper layer ISolate®. 
Use a small syringe with needle to slowly and carefully dispense 2 mL of lower layer 
ISolate® underneath the upper layer. 
6. Transfer the ISolate® gradient to a pre-warmed centrifuge carrier in incubator (39°C). 
7. Wash hemocytometer and coverslip with alcohol and place on microscope. 
8. Place some extra slides and coverslips on a warmer to use for checking sperm motility.  
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Semen Thaw and Preparation: 
9. After oocyte maturation, thaw two straws of semen in 39°C water for 30 seconds.  Be 
careful not to raise any remaining straws in the liquid nitrogen tank above the frost line. 
10. Dry straw and keep it warm and dark. Cut the sealed end off, hold it over the ISolate® 
gradient, and use a plunger to dispense semen on top of the upper layer.  
11. Check viability of the thawed semen by placing a drop of semen remaining in the straw 
onto a pre-warmed slide. View at 40X magnification to assure that motile sperm are 
present.  
12. Place the Isolate® gradient with semen into the pre-warmed centrifuge carrier and 
centrifuge at 400g for 20 minutes at 37°C.  
13. While the sperm is in the centrifuge, use this time to move the oocytes from maturation 
medium into IVF-TALP.  Wash thoroughly through the IVF-TALP wash dishes which 
were pre-equilibrated in the 5% CO2 incubator. 
14. Transfer up to 12 oocytes to each 48 µL drop of IVF-TALP located in the 5% CO2 
incubator. Return the 4-well plate back to the incubator when finished. 
15. After centrifuge stops, carefully remove carrier with the ISolate® gradient from the 
centrifuge. There should be a sperm pellet (if not, you must start over with a new 
gradient and semen). 
16. Using a 1 mL pipette, place the tip on the edge of the tube at the top of the ISolate® and 
slowly pull up the gradient until it is down to the sperm pellet. 
17. Wash with 5 mL IVF-TALP.  Centrifuge in a second pre-warmed carrier at 400g for 10 
minutes.  There will be another pellet.  Aspirate excess IVF-TALP. 
18.  Wash a second time with 2 mL IVF-TALP.  Centrifuge in a third pre-warmed carrier at 
400 X g for 5 minutes. When the centrifuge stops, aspirate the IVF-TALP down to the 
sperm pellet.  
19.  Determine sperm pellet concentration: 
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a. Add 95 µL of water into a small centrifuge tube. 
b. Gently swirl the sperm pellet to resuspend the sperm with any remaining 
medium. Transfer 5 µL of sperm suspension into the 95 µL of water in the small 
tube. Pipette gently to mix. 
c. Place the 15 mL tube with the rest of the sperm suspension into the 5% CO2 
incubator. Sperm must be kept warm. 
d. Add 10 µL of the sperm/water dilution to each side of the hemocytometer and 
wait a minute to allow sperm to settle to the bottom before counting. 
e. Count the sperm heads within five double-ruled squares on each side of the 
hemocytometer.  One side should not vary more than 10% from the other side (if 
so, clean the hemocytometer and count again). 
20. Dilute the sample in IVF-TALP: 
a. Average the counts from both counting fields.  This number, “X”, will be divided 
into 7500 to get the number of µL of sperm needed for the dilution.  Subtract the 
amount of sperm from 300 µL to obtain the amount of IVF-TALP to use.   
Example: 7500/X = µL of sperm; 300 - µL sperm = amount of IVF-TALP 
b. Add the appropriate amount of IVF-TALP medium to a microcentrifuge tube and 
then add the appropriate volume from the sperm pellet. Mix gently by pipetting. 
Fertilization: 
21. Add 2 µL of the final sperm suspension (to make a final concentration of 1x106 
sperm/mL) to each drop. Record the time and date on the dish. 
22. Incubate sperm and oocytes for 18 hours in a humidified incubator with 5% CO2 at 39°C. 
Culture: 
23. Prepare culture media. Media formulations can be found in Appendix B. 
24. Prepare dishes with HEPES-TALP for washing. 
25. Prepare dishes or 4-well plates with culture media for washing. 
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26. Make 35 µL drops of culture media in dishes.  Cover the drops with 570 µL of mineral oil 
that has been pre-warmed. Equilibrate dishes in the incubator for at least two hours. 
27. Strip off the cumulus cells: 
a. Thaw one vial of hyaluronidase (1 mg/mL). See Appendix B for solution 
formulations. 
b. Place in a 15 mL conical tube and incubate in the water bath for 2 minutes. 
c. Place the oocytes in the tube containing the hyaluronidase solution. 
d. Vortex at max speed for 5 minutes (or until the majority of cumulus cells are 
removed). 
28. Transfer the oocytes to a wash dish containing HEPES-TALP. 
29. After washing through HEPES-TALP, wash oocytes four times through culture media. 
30. Place 10 oocytes in each 35 µL drop of culture media.  
31. Incubate in 5% CO2 for 7 days (or change media at Day 3 if using a sequential media). 
Immunocytochemistry  
1. Place the embryos in a well containing PBST-BSA for 1 minute. 
2. Pre-fix embryos with 0.25% paraformaldehyde for 10 minutes at 37°C. 
3. Wash the embryos with PBS-PVA. Incubate for 10 minutes at 4°C. 
4. Place the embryos in 88% methanol for 1 minute. 
5. Transfer the embryos into 88% methanol and incubate for 30 minutes at -20°C. 
6. Wash embryos with PBST-BSA. 
7. Transfer the embryos into MAXblock™ blocking medium (15252, Active Motif®) and 
incubate for: 1 hour at 37°C, or 2 hours at 25°C, or overnight at 4°C. 
8. Aspirate the blocking media and add 1 mL of MAXwash™ washing medium (15254, 
Active motif®). Rock the plate for 10 minutes at room temperature on a rotating platform. 
9. Prepare the primary antibody dilution. 
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10. Aspirate the MAXwash and add 1 mL of primary antibody solution. Incubate for 1 hour at 
37°C. 
11. Aspirate the primary antibody solution and add 1 mL of MAXwash™ washing medium 
(15254, Active motif®). Rock the plate for 10 minutes at room temperature on a rotating 
platform. Repeat the wash two more times. 
12. Prepare the secondary antibody dilution. 
13. Aspirate the MAXwash and add 1 mL of secondary antibody solution. Incubate for 1 hour 
at 37°C. 
14. Aspirate the secondary antibody solution and add 1 mL of MAXwash™ washing medium 
(15254, Active motif®). Rock the plate for 10 minutes at room temperature on a rotating 
platform. Repeat the wash three more times. 
15. Prepare the Hoechst 33342 dilution.  
16. Aspirate the Hoechst solution and add 1 mL of MAXwash™ washing medium (15254, 
Active motif®). Rock the plate for 10 minutes at room temperature on a rotating platform. 
Repeat the wash one more time. 
17. Put the embryos on a clean microscope slide with a drop of commercial antifade. Post 
with silicone on a coverslip. Seal the edges of the coverslip with nail polish. Keep the 





STOCK SOLUTIONS AND MEDIA FORMULATIONS 
Stock Solutions 
1. Oocyte Collection Medium: Add 100 mL of 10X D-PBS solution (Sigma D-1283) to 900 
mL of autoclaved H2O to make 1 L of D-PBS.  Add 10 mL of Bovine Calf Serum 
(HyClone) and 1 mL of Heparin (Sagent Pharmaceuticals, Schaumburg, IL, USA) to 
make the D-PBS oocyte collection medium. 
2. Pen/Strep: Gibco 15140. Aliquot ≈500 µL of new pen/strep solution into sterile centrifuge 
tubes. Store at -20°C until use.  
3. Na Pyruvate: Sigma P-4562. Dissolve 22 mg of sodium pyruvate in 10 mL of sterile 
Millipore-Q water.  Sterile filter into an aluminum foil-wrapped 15 mL conical tube and 
store at 4°C for up to a month. 
4. L-Glutamine: Sigma G-8540. Make a 100X stock solution with a concentration of 200 
mM by dissolving 2.92 g of glutamine in 100 mL of water.  Aliquot 1.0 mL into sterile 
centrifuge tubes and store at -20°C. 
5. FSH: Folltropin-V (Bioniche). Make a 1000X stock solution (5 mg/mL) by diluting a 400 
mg vial of folltropin in 80 mL of water.  Store at -20°C in 100 µL aliquots. 
6. PH: First, make a 1 mM hypotaurine stock by dissolving 1.09 mg hypotaurine (H-1384) 
in 10 Ml 0.9% saline solution.  Then make a 2 mM penicillamine (P-4875) stock by 
adding 3 mg penicillamine to 10 mL 0.9% saline solution. Combine 2.5 mL hypotaurine 
stock, 2.5 mL penicillamine stock, and 4 mL 0.9% saline solution.  Sterile filter.  Store at 
-20°C in aliquots.  
7. Heparin: Add 2 mg of heparin (H-3149) to 8 mL IVF-TALP. Store at -20°C in 1 mL 
aliquots. 
8. Hyaluronidase: Sigma H-3506. Prepare a 1 mg/mL solution by dissolving 10 mg 
hyaluronidase into 10 mL of HEPES-TALP.  Aliquot 1 mL into 1.5 mL sterile centrifuge 






Component Source Product Number Amount 
BSA, Fraction V Sigma A-4503 60 mg 
HEPES-TL Caisson IVL01  20 mL 
Na Pyruvate stock solution P-4562 200 µL 
Pen/Strep Gibco 15140 200 µL 
Sterile filter. Date, label, and store at 4°C for no more than one week. 
 
Maturation Medium 
Component Source Product Number Amount 
Medium-199 Sigma M-4530 8.68 mL 
Fetal Bovine Serum cellgro 35-010-CV 1 mL 
Pen/Strep Gibco 15140 100 µL 
Na Pyruvate stock solution P-4562 100 µL 
Glutamine 100x stock solution G-8540 100 µL 
FSH (Folltropin) 1000x stock solution Bioniche 10 µL 
Sterile filter. Date, label, and store at 4°C for up to one week. 
 
 IVF-TALP Medium 
Component Source Product Number Amount 
TL-FERT Caisson IVL02 22.5 mL 
PH stock solution P-4875 / H-1384 1 mL 
Heparin stock solution H-3149 1 mL 
Pen/Strep Gibco 15140 100 µL 
Na Pyruvate stock solution P-4562 100 µL 
BSA Sigma A-6003 150 mg 
Sterile filter. Date, label, and store at 4°C for up to one week. 
 
SOFaa Culture Medium 
Component Source Product Number Amount 
SOF stock media Caisson IVL05 14.4 mL 
BME Sigma B-6766 300 µL 
MEM Sigma M-7145 150 µL 
Pen/Strep Gibco 15140 150 µL 
BSA Sigma A-4503 75 mg 




EQUIPMENT AND MATERIALS USED 
Transvaginal Ultrasound guided aspiration of cumulus-oocyte complexes (TUGA) 
 SonoSite® MicroMaxx® ultrasound system 
 7.5 MHz convex transducer (model C11e, SonoSite®) 
 Hard plastic probe handle equipped with accessories to accommodate short-needle 
collection systems 
 Plastic probe covers used to protect the transducer probe (273028-3436, Reproductive 
Resources™) 
 Sterilized non-spermicidal lubricating jelly (Priority care®, VetOne®) 
 Non-radiopaque polyethylene tubing (1.67 mm inner diameter and 2.42 mm outside 
diameter, Intramedic®) 
 Ureteral catheter connectors (050010, Cook Urological®) 
 EZ Way® Embryo collection filters (362829, Santa Cruz Animal Health™) 
 18 gauge X 1.5 inches Polypropylene hypodermic disposable needles (8881, Kendall® ) 
 18 gauge X 3.0 inches disposable needles (8300015026, Air-Tite Products Co., Inc.) 
 Lidocaine 2% (130954, VetOne®) 









ADDITIONAL DATA TABLES 
Table D.1. Geometric mean of housekeeping genes in Experiment One. 
Treatment Immature COCs In vitro Matured COCs In vivo Matured COCs 
Gene PolyA GADPH GeoMean PolyA GADPH GeoMean PolyA GADPH GeoMean 
Calibrator 26.560 28.950 27.729 26.560 28.950 27.729 26.560 28.950 27.729 
Sample 1 29.170 25.770 27.417 29.470 28.520 28.991 27.200 27.980 27.587 
Sample 2 30.780 29.570 30.169 29.247 28.787 29.016 26.400 25.250 25.819 
Sample 3 28.760 28.640 28.700 29.350 26.559 27.919 26.880 26.590 26.735 
Sample 4 30.860 27.320 29.036 30.122 29.723 29.922 27.130 26.600 26.864 
Sample 5 30.420 30.670 30.545 30.096 29.352 29.722 27.000 28.010 27.500 
Sample 6 30.950 27.150 28.988 30.321 28.886 29.595 26.100 24.210 25.137 
Sample 7 30.840 28.920 29.865 29.265 28.856 29.060 26.980 27.540 27.259 
Sample 8 30.500 30.870 30.684 26.916 26.740 26.828 27.000 25.880 26.434 
Sample 9 31.320 27.100 29.134 31.395 31.183 31.289 32.150 30.660 31.396 
Sample 10 32.060 29.620 30.816 31.820 31.472 31.646 28.470 27.060 27.756 
Sample 11 29.750 28.410 29.072 31.257 32.422 31.834 29.880 27.500 28.665 
Sample 12 28.850 25.580 27.166 30.969 30.506 30.736 30.770 27.960 29.331 
Sample 13 31.100 30.530 30.814 33.530 31.289 32.390 30.080 28.200 29.125 
Sample 14 31.020 26.720 28.790 35.550 29.950 32.630 27.460 25.230 26.321 
Sample 15 31.200 30.030 30.609 34.169 32.916 33.536 29.370 28.200 28.779 
Sample 16 31.620 30.490 31.050 20.671 20.796 20.733 30.390 26.510 28.384 
The geometrical mean between the CT values of housekeeping genes Poly A polymerase (PolyA) and Gliceraldehyde 3 phosphate 




Table D.2. QPCR values in Experiment One. 
Treatment Immature COCs In vitro Matured COCs In vivo Matured COCs 
Gene ASH1L EHMT2 SUV39H1 KDM6B ASH1L EHMT2 SUV39H1 KDM6B ASH1L EHMT2 SUV39H1 KDM6B 
Calibrator 25.337 25.040 27.072 28.248 25.337 25.040 27.072 28.248 25.337 25.040 27.072 28.248 
Sample 1 30.562 32.390 27.314 28.826 29.720 29.636 30.074 31.256 31.710 30.733 30.649 31.390 
Sample 2 32.651 34.025 25.793 29.156 27.504 26.096 27.535 25.837 20.193 28.937 27.975 27.393 
Sample 3 32.730 32.460 29.664 27.643 30.410 27.922 29.157 26.819 30.966 32.036 29.886 30.048 
Sample 4 30.973 28.333 27.972 27.426 31.292 27.803 31.160 30.513 29.173 32.562 29.634 31.088 
Sample 5 29.681 31.987 28.070 28.877 32.078 26.783 29.360 29.610 29.962 31.973 29.987 30.812 
Sample 6 32.922 33.294 29.416 28.293 28.709 26.279 28.237 28.472 26.260 28.883 27.891 27.770 
Sample 7 30.620 29.769 31.221 30.890 30.733 25.821 26.972 29.185 29.012 30.733 29.779 26.315 
Sample 8 34.423 33.790 28.394 28.939 30.606 24.904 28.274 28.113 29.535 32.412 29.530 28.681 
Sample 9 30.768 29.761 32.833 32.318 33.707 27.555 30.401 32.516 29.914 29.749 28.009 32.968 
Sample 10 33.246 30.079 35.208 32.349 33.540 30.789 30.109 31.890 28.577 27.221 28.305 28.656 
Sample 11 31.789 29.178 32.523 30.269 31.817 32.585 31.810 31.202 31.285 28.926 28.813 32.037 
Sample 12 30.484 26.506 29.891 30.525 30.354 32.235 31.389 31.915 33.350 29.810 29.505 32.572 
Sample 13 29.468 28.479 31.305 32.639 30.413 34.665 30.846 24.123 31.467 29.053 28.265 31.978 
Sample 14 32.900 29.522 33.313 31.471 30.179 32.832 35.236 31.919 26.365 27.520 27.713 28.878 
Sample 15 25.132 28.529 31.191 31.058 32.576 28.631 28.783 27.036 30.449 29.279 29.476 27.286 
Sample 16 34.293 30.056 31.159 31.383 17.473 22.986 20.933 21.226 33.742 29.799 29.857 32.773 
The QPCR values (Ct values) of each sample in each treatment in Experiment One. Four genes of interest: 1ASH1L: Bos taurus 
absent, small, or homeotic-like Drosophila, mRNA; EHMT2: Bos taurus euchromatic histone-lysine N-methyltransferase 2, mRNA; 
SUV31: Bos taurus suppressor of variegation 3-9 homologue 1, mRNA; KDM6B: PREDICTED: Bos taurus lysine (K)-Specific 







Table D.3. Geometric mean of housekeeping genes in Experiment Two. 
Treatment Immature Oocytes In vitro Matured Oocytes In vivo Matured Oocytes 
Gene PolyA GADPH GeoMean PolyA GADPH GeoMean PolyA GADPH GeoMean 
Calibrator 26.592 29.187 27.859 29.187 28.516 28.849 29.187 29.018 29.102 
Sample 1 32.175 29.883 31.008 29.012 28.114 28.560 31.939 32.175 32.057 
Sample 2 29.160 29.459 29.309 29.857 30.078 29.968 30.945 30.927 30.936 
Sample 3 29.418 27.103 28.237 29.505 29.665 29.585 31.490 28.913 30.174 
Sample 4 29.565 29.602 29.583 30.005 28.199 29.088 31.569 28.481 29.985 
Sample 5 29.974 29.675 29.824 32.810 34.314 33.554 30.858 31.499 31.177 
Sample 6 29.795 28.160 28.966 31.575 30.499 31.032 32.225 31.596 31.909 
Sample 7 29.405 27.955 28.670 27.824 28.540 28.179 31.730 31.319 31.524 
The geometrical mean between the CT values of housekeeping genes Poly A polymerase (PolyA) and Gliceraldehyde 3 phosphate 









Table D.4. QPCR values in Experiment Two. 
Treatment Immature Oocytes In vitro Matured Oocytes In vivo Matured Oocytes 
Gene ASH1L EHMT2 SUV39H1 KDM6B ASH1L EHMT2 SUV39H1 KDM6B ASH1L EHMT2 SUV39H1 KDM6B 
Calibrator 25.476 26.832 26.613 24.346 25.476 26.832 26.613 24.346 25.476 26.832 26.613 24.346 
Sample 1 35.024 33.048 31.411 33.140 32.744 31.373 30.900 30.719 35.473 36.143 33.765 32.892 
Sample 2 28.771 30.389 30.760 30.774 34.322 32.330 32.424 31.943 36.562 32.915 32.199 34.222 
Sample 3 32.293 30.802 30.629 29.189 34.372 32.678 31.304 32.740 33.339 33.589 30.527 35.119 
Sample 4 33.874 31.134 30.453 31.155 32.666 31.155 30.570 30.729 35.147 33.623 32.793 31.170 
Sample 5 33.819 31.487 29.874 31.605 33.266 33.285 30.305 32.340 35.746 33.196 31.945 ------- 
Sample 6 33.672 29.785 30.354 30.295 33.423 31.225 29.270 31.725 33.966 31.409 32.399 33.167 
Sample 7 25.503 32.204 31.180 31.600 27.250 28.164 27.825 25.664 34.424 31.365 29.690 34.308 
The QPCR values (Ct values) of each sample in each treatment in Experiment Two. Four genes of interest: 1ASH1L: Bos taurus 
absent, small, or homeotic-like Drosophila, mRNA; EHMT2: Bos taurus euchromatic histone-lysine N-methyltransferase 2, mRNA; 
SUV31: Bos taurus suppressor of variegation 3-9 homologue 1, mRNA; KDM6B: PREDICTED: Bos taurus lysine (K)-Specific 







Table D.5. Geometric mean of housekeeping genes in Experiment Three. 
Treatment Immature Cumulus Cells In vitro Matured Cumulus Cells In vivo Matured Cumulus Cells 
Gene PolyA GADPH GeoMean PolyA GADPH GeoMean PolyA GADPH GeoMean 
Calibrator 26.592 29.187 27.859 26.592 29.187 27.859 26.592 29.187 27.859 
Sample 1 29.215 24.771 26.901 26.964 24.941 25.933 30.829 25.784 28.194 
Sample 2 27.364 21.655 24.343 26.474 25.055 25.755 27.384 21.839 24.455 
Sample 3 30.400 27.060 28.681 26.947 25.129 26.022 26.895 21.650 24.130 
Sample 4 29.458 23.980 26.578 26.940 25.128 26.018 29.345 23.787 26.420 
Sample 5 31.032 25.251 27.993 27.500 26.055 26.768 26.139 20.889 23.367 
Sample 6 30.015 25.118 27.458 28.700 27.963 28.329 25.398 20.903 23.041 
Sample 7 30.410 24.949 27.544 27.129 25.370 26.235 28.155 21.870 24.814 
The geometrical mean between the CT values of housekeeping genes Poly A polymerase (PolyA) and Gliceraldehyde 3 mphosphate 











Table D.6. QPCR values in Experiment Three. 
Treatment Immature Cumulus Cells In vitro Matured Cumulus Cells In vivo Matured Cumulus Cells 
Gene ASH1L EHMT2 SUV39H1 KDM6B ASH1L EHMT2 SUV39H1 KDM6B ASH1L EHMT2 SUV39H1 KDM6B 
Calibrator 25.476 26.832 26.613 24.346 25.476 26.832 26.613 24.346 25.476 26.832 26.613 24.346 
Sample 1 32.580 32.105 31.747 30.800 31.122 29.563 33.220 28.740 33.062 33.224 34.219 33.119 
Sample 2 31.348 29.570 29.790 31.146 27.626 31.572 31.120 29.874 30.548 30.084 32.533 28.536 
Sample 3 33.875 33.770 34.565 32.659 30.745 30.815 30.465 29.715 29.702 29.030 29.562 30.178 
Sample 4 33.028 31.750 31.900 31.829 30.693 30.402 31.751 28.744 31.082 32.227 32.798 32.543 
Sample 5 33.558 32.795 33.060 33.075 31.683 31.525 30.763 29.744 30.253 29.432 29.558 28.240 
Sample 6 32.240 33.123 28.340 31.654 27.104 30.127 28.978 28.656 30.145 31.513 31.194 29.245 
Sample 7 32.925 31.700 32.183 33.085 31.008 29.806 31.209 30.435 31.131 29.965 29.885 32.342 
The QPCR values (Ct values) of each sample in each treatment in Experiment Three. Four genes of interest: 1ASH1L: Bos taurus 
absent, small, or homeotic-like Drosophila, mRNA; EHMT2: Bos taurus euchromatic histone-lysine N-methyltransferase 2, mRNA; 












1 1 1,111,376 104,633 1,006,743 
1 2 551,381 115,026 436,355 
1 3 1,264,551 140,665 1,123,886 
1 4 167,211 108,968 58,243 
1 5 236,036 69,799 166,237 
1 6 166,387 144,201 22,186 
2 7 2,352,915 59,326 2,293,589 
2 8 1,986,862 366,063 1,620,799 
2 9 9,082,480 57,455 9,025,025 
2 10 8,295,104 198,619 8,096,485 
2 11 2,702,502 255,354 2,447,148 
2 12 2,989,271 274,459 2,714,812 
2 13 8,926,342 283,338 8,643,004 
2 14 5,015,970 312,455 4,703,515 
2 15 468,357 234,127 234,230 
2 16 3,939,362 81,171 3,858,191 
2 17 2,380,149 312,026 2,068,123 
2 18 6,921,490 80,207 6,841,283 
2 19 5,610,019 305,336 5,304,683 
2 20 12,874,420 341,950 12,532,470 
2 21 1,391,339 55,125 1,336,214 
2 22 6,071,813 338,505 5,733,308 
2 23 6,865,661 214,161 6,651,500 
2 24 5,471,721 221,860 5,249,861 
2 25 6,060,546 327,728 5,732,818 
2 26 5,943,178 128,974 5,814,204 
2 27 6,174,976 211,425 5,963,551 
2 28 7,054,145 295,985 6,758,160 
2 29 2,791,172 257,710 2,533,462 
2 30 6,763,926 285,565 6,478,361 
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Table D.8. Fluorescent intensity data for Experiment Five. 










1 1 1 396591 5316 391275 
1 1 2 140803 5316 135487 
1 1 3 176298 5316 170982 
1 1 4 108005 5316 102689 
1 2 5 91385 2346 89039 
1 2 6 133704 2346 131358 
1 2 7 78007 2346 75661 
1 2 8 198910 2346 196564 
1 2 9 289810 2346 287464 
1 3 10 60397 2792 57605 
1 3 11 65847 2792 63055 
1 3 12 71259 2792 68467 
1 3 13 73785 2792 70993 
1 3 14 106132 2792 103340 
1 3 15 129518 2792 126726 
1 4 16 132662 3986 128676 
1 4 17 140640 3986 136654 
1 4 18 73782 3986 69796 
1 4 19 79420 3986 75434 
1 5 20 308157 2345 305812 
1 5 21 139687 2345 137342 
1 6 22 295707 4963 290744 
1 6 23 257329 4963 252366 
1 6 24 202985 4963 198022 
1 6 25 124906 4963 119943 
1 7 26 211560 3954 207606 
1 7 27 187462 3954 183508 
1 7 28 240731 3954 236777 




(Table D.8 continued) 










1 8 30 139093 1965 137128 
1 8 31 136540 1965 134575 
1 9 32 115054 3467 111587 
1 9 33 131282 3467 127815 
1 9 34 114423 3467 110956 
1 9 35 221551 3467 218084 
1 10 36 110841 2335 108506 
1 10 37 188236 2335 185901 
1 10 38 205737 2335 203402 
1 11 39 245923 4322 241601 
1 11 40 186170 4322 181848 
1 11 41 132319 4322 127997 
1 11 42 76260 4322 71938 
1 12 43 127755 2960 124795 
1 12 44 150050 2960 147090 
1 12 45 108572 2960 105612 
1 12 46 129536 2960 126576 
1 13 47 262503 3998 258505 
1 13 48 85442 3998 81444 
1 14 49 56153 1868 54285 
1 14 50 98669 1868 96801 
1 14 51 166421 1868 164553 
1 14 52 68002 1868 66134 
1 15 53 114755 2625 112130 
1 15 54 58465 2625 55840 
1 15 55 71131 2625 68506 
1 15 56 63344 2625 60719 
1 16 57 237874 3345 234529 
1 16 58 115074 3345 111729 
1 16 59 87417 3345 84072 
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(Table D.8 continued) 










1 16 60 16599 3345 13254 
1 17 61 173015 3103 169912 
1 17 62 81184 3103 78081 
1 17 63 153555 3103 150452 
1 17 64 140724 3103 137621 
1 18 65 31078 1320 29758 
1 18 66 45265 1320 43945 
1 18 67 45316 1320 43996 
1 18 68 25342 1320 24022 
1 18 69 43984 1320 42664 
1 18 70 4530 1320 3210 
1 18 71 38990 1320 37670 
1 18 72 242690 1320 241370 
1 19 73 128832 2556 126276 
1 19 74 94276 2556 91720 
1 19 75 128349 2556 125793 
1 19 76 129143 2556 126587 
1 20 77 162410 3145 159265 
1 20 78 194417 3145 191272 
1 20 79 178399 3145 175254 
1 20 80 88110 3145 84965 
1 21 81 198322 4648 193674 
1 21 82 180658 4648 176010 
1 21 83 104984 4648 100336 
1 21 84 320375 4648 315727 
1 21 85 83773 4648 79125 
1 22 86 238039 5412 232627 
1 22 87 89060 5412 83648 
1 22 88 243346 5412 237934 
1 22 89 228552 5412 223140 
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(Table D.8 continued) 










2 23 90 320681 3966 316715 
2 23 91 307291 3966 303325 
2 23 92 204435 3966 200469 
2 24 93 392751 6745 386006 
2 24 94 301726 6745 294981 
2 25 95 70457 1336 69121 
2 25 96 166056 1336 164720 
2 25 97 112709 1336 111373 
2 26 98 297061 2546 294515 
2 26 99 109370 2546 106824 
2 26 100 83105 2546 80559 
2 26 101 115812 2546 113266 
2 26 102 259442 2546 256896 
2 26 103 112607 2546 110061 
2 26 104 103344 2546 100798 
2 26 105 135027 2546 132481 
2 27 106 585289 6539 578750 
2 27 107 288730 6539 282191 
2 27 108 113611 6539 107072 
2 27 109 68253 6539 61714 
2 28 110 280447 1978 278469 
2 28 111 193172 1978 191194 
2 28 112 138532 1978 136554 
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